CN115043844B - Trk激酶抑制剂化合物及其用途 - Google Patents
Trk激酶抑制剂化合物及其用途 Download PDFInfo
- Publication number
- CN115043844B CN115043844B CN202210705163.4A CN202210705163A CN115043844B CN 115043844 B CN115043844 B CN 115043844B CN 202210705163 A CN202210705163 A CN 202210705163A CN 115043844 B CN115043844 B CN 115043844B
- Authority
- CN
- China
- Prior art keywords
- ethoxy
- difluorophenyl
- imidazol
- alkyl
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 152
- 229940096912 Trk tyrosine kinase inhibitor Drugs 0.000 title abstract description 4
- 150000003839 salts Chemical class 0.000 claims abstract description 32
- 230000003287 optical effect Effects 0.000 claims abstract description 25
- -1 methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, cyclopropyl Chemical group 0.000 claims description 150
- 125000000217 alkyl group Chemical group 0.000 claims description 74
- 125000003545 alkoxy group Chemical group 0.000 claims description 45
- 101000596894 Homo sapiens High affinity nerve growth factor receptor Proteins 0.000 claims description 33
- 150000002367 halogens Chemical class 0.000 claims description 33
- 125000003118 aryl group Chemical group 0.000 claims description 31
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 30
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 29
- 125000001424 substituent group Chemical group 0.000 claims description 29
- 125000002619 bicyclic group Chemical group 0.000 claims description 28
- 229910052736 halogen Inorganic materials 0.000 claims description 28
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims description 27
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 27
- 125000001072 heteroaryl group Chemical group 0.000 claims description 22
- 201000010099 disease Diseases 0.000 claims description 21
- 108090000623 proteins and genes Proteins 0.000 claims description 19
- 206010028980 Neoplasm Diseases 0.000 claims description 16
- 125000002723 alicyclic group Chemical group 0.000 claims description 16
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 15
- 229910052799 carbon Inorganic materials 0.000 claims description 14
- 229910052739 hydrogen Inorganic materials 0.000 claims description 14
- 229910052757 nitrogen Inorganic materials 0.000 claims description 14
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 13
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 13
- 125000002757 morpholinyl group Chemical group 0.000 claims description 13
- 229910052760 oxygen Inorganic materials 0.000 claims description 13
- 229910052717 sulfur Inorganic materials 0.000 claims description 13
- 206010061218 Inflammation Diseases 0.000 claims description 12
- 125000003386 piperidinyl group Chemical group 0.000 claims description 12
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 11
- 230000004054 inflammatory process Effects 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- 125000004193 piperazinyl group Chemical group 0.000 claims description 10
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 10
- 125000004767 (C1-C4) haloalkoxy group Chemical group 0.000 claims description 9
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 9
- 208000002193 Pain Diseases 0.000 claims description 8
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 8
- 208000035475 disorder Diseases 0.000 claims description 8
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 7
- 229910052794 bromium Inorganic materials 0.000 claims description 7
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 7
- 201000011510 cancer Diseases 0.000 claims description 6
- 230000004663 cell proliferation Effects 0.000 claims description 6
- 230000036407 pain Effects 0.000 claims description 6
- 125000002853 C1-C4 hydroxyalkyl group Chemical group 0.000 claims description 5
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 5
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 4
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 4
- 206010009944 Colon cancer Diseases 0.000 claims description 4
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 4
- 201000001441 melanoma Diseases 0.000 claims description 4
- 230000004770 neurodegeneration Effects 0.000 claims description 4
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 4
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- UMXJGGUAKDLDLP-UHFFFAOYSA-N CC(C1=CC(F)=CC(F)=C1)OC(C=C12)=CC=C1NN=C2C1=NC(CN(C2)C(C3CCN(C)CC3)=O)=C2N1 Chemical compound CC(C1=CC(F)=CC(F)=C1)OC(C=C12)=CC=C1NN=C2C1=NC(CN(C2)C(C3CCN(C)CC3)=O)=C2N1 UMXJGGUAKDLDLP-UHFFFAOYSA-N 0.000 claims description 3
- UNPMFJWLWWIBNC-UHFFFAOYSA-N CC(C1=CC(F)=CC(F)=C1)OC(C=C12)=CC=C1NN=C2C1=NC(CN(C2)C(O)=O)=C2N1C1CCN(C)CC1 Chemical compound CC(C1=CC(F)=CC(F)=C1)OC(C=C12)=CC=C1NN=C2C1=NC(CN(C2)C(O)=O)=C2N1C1CCN(C)CC1 UNPMFJWLWWIBNC-UHFFFAOYSA-N 0.000 claims description 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
- 206010029260 Neuroblastoma Diseases 0.000 claims description 3
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 3
- 208000005017 glioblastoma Diseases 0.000 claims description 3
- 125000003037 imidazol-2-yl group Chemical group [H]N1C([*])=NC([H])=C1[H] 0.000 claims description 3
- 201000005202 lung cancer Diseases 0.000 claims description 3
- 208000020816 lung neoplasm Diseases 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 201000002510 thyroid cancer Diseases 0.000 claims description 3
- 125000004211 3,5-difluorophenyl group Chemical group [H]C1=C(F)C([H])=C(*)C([H])=C1F 0.000 claims description 2
- TUOAYDFDVSJVHV-UHFFFAOYSA-N CC(C1=CC(F)=CC(F)=C1)OC(C=C12)=CC=C1NN=C2C1=NC(CN(C2)C(N(C)C)=O)=C2N1 Chemical compound CC(C1=CC(F)=CC(F)=C1)OC(C=C12)=CC=C1NN=C2C1=NC(CN(C2)C(N(C)C)=O)=C2N1 TUOAYDFDVSJVHV-UHFFFAOYSA-N 0.000 claims description 2
- FTKDCAYZYJKNEF-UHFFFAOYSA-N CC(C1=CC(F)=CC(F)=C1)OC(C=C12)=CC=C1NN=C2C1=NC(CN(C2)C3CCN(C)CC3)=C2N1 Chemical compound CC(C1=CC(F)=CC(F)=C1)OC(C=C12)=CC=C1NN=C2C1=NC(CN(C2)C3CCN(C)CC3)=C2N1 FTKDCAYZYJKNEF-UHFFFAOYSA-N 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 claims 3
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 claims 1
- LFSDNHNTJOFVMY-UHFFFAOYSA-N CC(C1=CC(F)=CC(F)=C1)OC(C=C12)=CC=C1NN=C2C1=NC(CCN(C2)C3CCN(C)CC3)=C2N1 Chemical compound CC(C1=CC(F)=CC(F)=C1)OC(C=C12)=CC=C1NN=C2C1=NC(CCN(C2)C3CCN(C)CC3)=C2N1 LFSDNHNTJOFVMY-UHFFFAOYSA-N 0.000 claims 1
- JDHXYJZVNOQWBG-UHFFFAOYSA-N CC(C1=CC(F)=CC(F)=C1)OC(C=C12)=CC=C1NN=C2C1=NC(CN(C2)C(C3)CC33CCN(C)CC3)=C2N1 Chemical compound CC(C1=CC(F)=CC(F)=C1)OC(C=C12)=CC=C1NN=C2C1=NC(CN(C2)C(C3)CC33CCN(C)CC3)=C2N1 JDHXYJZVNOQWBG-UHFFFAOYSA-N 0.000 claims 1
- QCEISZKXEHIIGR-UHFFFAOYSA-N CC(C1=CC(F)=CC(F)=C1)OC(C=C12)=CC=C1NN=C2C1=NC(CN(C2)C(C3)CC33CN(C)C3)=C2N1 Chemical compound CC(C1=CC(F)=CC(F)=C1)OC(C=C12)=CC=C1NN=C2C1=NC(CN(C2)C(C3)CC33CN(C)C3)=C2N1 QCEISZKXEHIIGR-UHFFFAOYSA-N 0.000 claims 1
- POJKNUDAOUZFGY-UHFFFAOYSA-N CC(C1=CC(F)=CC(F)=C1)OC(C=C12)=CC=C1NN=C2C1=NC(CN(C2)C(C3)CC3N(C)C)=C2N1 Chemical compound CC(C1=CC(F)=CC(F)=C1)OC(C=C12)=CC=C1NN=C2C1=NC(CN(C2)C(C3)CC3N(C)C)=C2N1 POJKNUDAOUZFGY-UHFFFAOYSA-N 0.000 claims 1
- HYTXORZVJDVALM-UHFFFAOYSA-N CC(C1=CC(F)=CC(F)=C1)OC(C=C12)=CC=C1NN=C2C1=NC(CN(C2)C(CC3)CCC3N(C)C)=C2N1 Chemical compound CC(C1=CC(F)=CC(F)=C1)OC(C=C12)=CC=C1NN=C2C1=NC(CN(C2)C(CC3)CCC3N(C)C)=C2N1 HYTXORZVJDVALM-UHFFFAOYSA-N 0.000 claims 1
- XSPXABGVTCNRKW-UHFFFAOYSA-N CC(C1=CC(F)=CC(F)=C1)OC(C=C12)=CC=C1NN=C2C1=NC(CN(C2)C(CCC3)CC3N(C)C)=C2N1 Chemical compound CC(C1=CC(F)=CC(F)=C1)OC(C=C12)=CC=C1NN=C2C1=NC(CN(C2)C(CCC3)CC3N(C)C)=C2N1 XSPXABGVTCNRKW-UHFFFAOYSA-N 0.000 claims 1
- BHHOPSDKZGAOEF-UHFFFAOYSA-N CC(C1=CC(F)=CC(F)=C1)OC(C=C12)=CC=C1NN=C2C1=NC(CN(C2)C(N3CCN(C)CC3)=O)=C2N1 Chemical compound CC(C1=CC(F)=CC(F)=C1)OC(C=C12)=CC=C1NN=C2C1=NC(CN(C2)C(N3CCN(C)CC3)=O)=C2N1 BHHOPSDKZGAOEF-UHFFFAOYSA-N 0.000 claims 1
- FCTQJBQLZSUWRU-UHFFFAOYSA-N CC(C1=CC(F)=CC(F)=C1)OC(C=C12)=CC=C1NN=C2C1=NC(CN(C2)C(O)=O)=C2N1C1CN(C)C1 Chemical compound CC(C1=CC(F)=CC(F)=C1)OC(C=C12)=CC=C1NN=C2C1=NC(CN(C2)C(O)=O)=C2N1C1CN(C)C1 FCTQJBQLZSUWRU-UHFFFAOYSA-N 0.000 claims 1
- RQKSSYXAAUXNDP-UHFFFAOYSA-N CC(C1=CC(F)=CC(F)=C1)OC(C=C12)=CC=C1NN=C2C1=NC(CN(C2)C3CN(C)CC3)=C2N1 Chemical compound CC(C1=CC(F)=CC(F)=C1)OC(C=C12)=CC=C1NN=C2C1=NC(CN(C2)C3CN(C)CC3)=C2N1 RQKSSYXAAUXNDP-UHFFFAOYSA-N 0.000 claims 1
- DBKPHEZKNBKFFF-UHFFFAOYSA-N CC(C1=CC(F)=CC(F)=C1)OC(C=C12)=CC=C1NN=C2C1=NC(CN(CC(CC2)CCN2C(C)=O)C2)=C2N1 Chemical compound CC(C1=CC(F)=CC(F)=C1)OC(C=C12)=CC=C1NN=C2C1=NC(CN(CC(CC2)CCN2C(C)=O)C2)=C2N1 DBKPHEZKNBKFFF-UHFFFAOYSA-N 0.000 claims 1
- HGXGGQOVUWJFOE-UHFFFAOYSA-N CC(C1=CC(F)=CC(F)=C1)OC(C=C12)=CC=C1NN=C2C1=NC(CN(CC(CC2)CCN2C2CCC2)C2)=C2N1 Chemical compound CC(C1=CC(F)=CC(F)=C1)OC(C=C12)=CC=C1NN=C2C1=NC(CN(CC(CC2)CCN2C2CCC2)C2)=C2N1 HGXGGQOVUWJFOE-UHFFFAOYSA-N 0.000 claims 1
- KHPQQGAJBLUVAW-UHFFFAOYSA-N CC(C1=CC(F)=CC(F)=C1)OC(C=C12)=CC=C1NN=C2C1=NC(CN(CC2CCNCC2)C2)=C2N1 Chemical compound CC(C1=CC(F)=CC(F)=C1)OC(C=C12)=CC=C1NN=C2C1=NC(CN(CC2CCNCC2)C2)=C2N1 KHPQQGAJBLUVAW-UHFFFAOYSA-N 0.000 claims 1
- HVXQNCKIFBCVNJ-UHFFFAOYSA-N CC(C1=CC(F)=CC(F)=C1)OC(C=C12)=CC=C1NN=C2C1=NC(CN(CC2CN(C)C2)C2)=C2N1 Chemical compound CC(C1=CC(F)=CC(F)=C1)OC(C=C12)=CC=C1NN=C2C1=NC(CN(CC2CN(C)C2)C2)=C2N1 HVXQNCKIFBCVNJ-UHFFFAOYSA-N 0.000 claims 1
- WZEJNNXABIXCOM-UHFFFAOYSA-N CC(C1=CC(F)=CC(F)=C1)OC(C=C12)=CC=C1NN=C2C1=NC(CN(CC2CNCCC2)C2)=C2N1 Chemical compound CC(C1=CC(F)=CC(F)=C1)OC(C=C12)=CC=C1NN=C2C1=NC(CN(CC2CNCCC2)C2)=C2N1 WZEJNNXABIXCOM-UHFFFAOYSA-N 0.000 claims 1
- QZLOFQOCPOPDRU-UHFFFAOYSA-N CC(C1=CC(F)=CC(F)=C1)OC(C=C12)=CC=C1NN=C2C1=NC(CN(CC2NCCC2)C2)=C2N1 Chemical compound CC(C1=CC(F)=CC(F)=C1)OC(C=C12)=CC=C1NN=C2C1=NC(CN(CC2NCCC2)C2)=C2N1 QZLOFQOCPOPDRU-UHFFFAOYSA-N 0.000 claims 1
- FLZSROLJHSFDPW-UHFFFAOYSA-N CC(C1=CC(F)=CC(F)=C1)OC(C=C12)=CC=C1NN=C2C1=NC(CN(CC2NCCCC2)C2)=C2N1 Chemical compound CC(C1=CC(F)=CC(F)=C1)OC(C=C12)=CC=C1NN=C2C1=NC(CN(CC2NCCCC2)C2)=C2N1 FLZSROLJHSFDPW-UHFFFAOYSA-N 0.000 claims 1
- MCPCTCJVGCNYIS-UHFFFAOYSA-N CC(C1=CC(F)=CC(F)=C1)OC(C=C12)=CC=C1NN=C2C1=NC(CN(CCC2CCN(C)CC2)C2)=C2N1 Chemical compound CC(C1=CC(F)=CC(F)=C1)OC(C=C12)=CC=C1NN=C2C1=NC(CN(CCC2CCN(C)CC2)C2)=C2N1 MCPCTCJVGCNYIS-UHFFFAOYSA-N 0.000 claims 1
- GNSBYJSVUCPHAO-UHFFFAOYSA-N CC(C1CN(C)C1)N(C1)CC2=C1NC(C(C1=C3)=NNC1=CC=C3OC(C)C1=CC(F)=CC(F)=C1)=N2 Chemical compound CC(C1CN(C)C1)N(C1)CC2=C1NC(C(C1=C3)=NNC1=CC=C3OC(C)C1=CC(F)=CC(F)=C1)=N2 GNSBYJSVUCPHAO-UHFFFAOYSA-N 0.000 claims 1
- IZNXHTNNUCPJRG-UHFFFAOYSA-N CCC(C1=CC(F)=CC(F)=C1)OC(C=C12)=CC=C1NN=C2C1=NC(CN(CC2CCN(C)CC2)C2)=C2N1 Chemical compound CCC(C1=CC(F)=CC(F)=C1)OC(C=C12)=CC=C1NN=C2C1=NC(CN(CC2CCN(C)CC2)C2)=C2N1 IZNXHTNNUCPJRG-UHFFFAOYSA-N 0.000 claims 1
- RDOHHGNRQBHNLV-UHFFFAOYSA-N CCN(CC1)CCC1N(C1)CC2=C1NC(C(C1=C3)=NNC1=CC=C3OC(C)C1=CC(F)=CC(F)=C1)=N2 Chemical compound CCN(CC1)CCC1N(C1)CC2=C1NC(C(C1=C3)=NNC1=CC=C3OC(C)C1=CC(F)=CC(F)=C1)=N2 RDOHHGNRQBHNLV-UHFFFAOYSA-N 0.000 claims 1
- DXLFXLFABYHRAW-UHFFFAOYSA-N CCN(CCC1)CC1N(C1)CC2=C1NC(C(C1=C3)=NNC1=CC=C3OC(C)C1=CC(F)=CC(F)=C1)=N2 Chemical compound CCN(CCC1)CC1N(C1)CC2=C1NC(C(C1=C3)=NNC1=CC=C3OC(C)C1=CC(F)=CC(F)=C1)=N2 DXLFXLFABYHRAW-UHFFFAOYSA-N 0.000 claims 1
- VUJHHFQMHIGGII-UHFFFAOYSA-N CN(CC1)CCC1N(C1)CC2=C1NC(C1=NNC3=CC=C(CC4=CC(F)=CC(F)=C4)C=C13)=N2 Chemical compound CN(CC1)CCC1N(C1)CC2=C1NC(C1=NNC3=CC=C(CC4=CC(F)=CC(F)=C4)C=C13)=N2 VUJHHFQMHIGGII-UHFFFAOYSA-N 0.000 claims 1
- VLIHNLLQNQTLLI-UHFFFAOYSA-N CS(N(C1)CC2=C1NC(C1=NNC3=CC=C(CC4=CC(F)=CC(F)=C4)C=C13)=N2)(=O)=O Chemical compound CS(N(C1)CC2=C1NC(C1=NNC3=CC=C(CC4=CC(F)=CC(F)=C4)C=C13)=N2)(=O)=O VLIHNLLQNQTLLI-UHFFFAOYSA-N 0.000 claims 1
- BJUQOKOVRWUDBY-UHFFFAOYSA-N O=C(C1CC1)N(C1)CC2=C1NC(C1=NNC3=CC=C(CC4=CC(F)=CC(F)=C4)C=C13)=N2 Chemical compound O=C(C1CC1)N(C1)CC2=C1NC(C1=NNC3=CC=C(CC4=CC(F)=CC(F)=C4)C=C13)=N2 BJUQOKOVRWUDBY-UHFFFAOYSA-N 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 41
- 239000002207 metabolite Substances 0.000 abstract description 7
- 239000000651 prodrug Substances 0.000 abstract description 7
- 229940002612 prodrug Drugs 0.000 abstract description 7
- 239000000543 intermediate Substances 0.000 description 173
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 104
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 81
- 238000006243 chemical reaction Methods 0.000 description 81
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 63
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 48
- 239000012074 organic phase Substances 0.000 description 47
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 44
- 238000003786 synthesis reaction Methods 0.000 description 43
- 230000015572 biosynthetic process Effects 0.000 description 41
- 239000000243 solution Substances 0.000 description 38
- 125000004432 carbon atom Chemical group C* 0.000 description 36
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 33
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 33
- 239000000741 silica gel Substances 0.000 description 33
- 229910002027 silica gel Inorganic materials 0.000 description 33
- 102100035108 High affinity nerve growth factor receptor Human genes 0.000 description 31
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 26
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 26
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 25
- 238000005160 1H NMR spectroscopy Methods 0.000 description 24
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 20
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 17
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 17
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 16
- 125000005842 heteroatom Chemical group 0.000 description 14
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 14
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 12
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- 125000003342 alkenyl group Chemical group 0.000 description 12
- 235000011114 ammonium hydroxide Nutrition 0.000 description 12
- 125000005843 halogen group Chemical group 0.000 description 12
- 229910052740 iodine Inorganic materials 0.000 description 12
- 125000004429 atom Chemical group 0.000 description 11
- 239000012467 final product Substances 0.000 description 11
- 229910052731 fluorine Inorganic materials 0.000 description 11
- 150000003254 radicals Chemical class 0.000 description 11
- 239000007858 starting material Substances 0.000 description 11
- 238000001308 synthesis method Methods 0.000 description 11
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 10
- 239000000460 chlorine Substances 0.000 description 10
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 10
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 108091000080 Phosphotransferase Proteins 0.000 description 9
- 125000000304 alkynyl group Chemical group 0.000 description 9
- 230000005764 inhibitory process Effects 0.000 description 9
- 239000011630 iodine Substances 0.000 description 9
- 102000020233 phosphotransferase Human genes 0.000 description 9
- 239000011541 reaction mixture Substances 0.000 description 9
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 8
- 125000002393 azetidinyl group Chemical group 0.000 description 8
- 229910052801 chlorine Inorganic materials 0.000 description 8
- 238000000605 extraction Methods 0.000 description 8
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 7
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 7
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 7
- 235000008504 concentrate Nutrition 0.000 description 7
- 239000012141 concentrate Substances 0.000 description 7
- 235000019441 ethanol Nutrition 0.000 description 7
- 239000011737 fluorine Substances 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 6
- 241000282414 Homo sapiens Species 0.000 description 6
- 101100446506 Mus musculus Fgf3 gene Proteins 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 6
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 6
- 206010025323 Lymphomas Diseases 0.000 description 5
- 102000001253 Protein Kinase Human genes 0.000 description 5
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 125000004093 cyano group Chemical group *C#N 0.000 description 5
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 125000001188 haloalkyl group Chemical group 0.000 description 5
- 239000001257 hydrogen Substances 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 5
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 5
- 125000004433 nitrogen atom Chemical group N* 0.000 description 5
- 125000003566 oxetanyl group Chemical group 0.000 description 5
- 125000006239 protecting group Chemical group 0.000 description 5
- 108060006633 protein kinase Proteins 0.000 description 5
- 239000011535 reaction buffer Substances 0.000 description 5
- 125000006413 ring segment Chemical group 0.000 description 5
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical class [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 5
- BOCWGBMVJKSUOD-UHFFFAOYSA-N tert-butyl 1h-imidazole-5-carboxylate Chemical compound CC(C)(C)OC(=O)C1=CN=CN1 BOCWGBMVJKSUOD-UHFFFAOYSA-N 0.000 description 5
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 5
- RQCNHUCCQJMSRG-UHFFFAOYSA-N tert-butyl piperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCCC1 RQCNHUCCQJMSRG-UHFFFAOYSA-N 0.000 description 5
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 5
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 5
- 125000002053 thietanyl group Chemical group 0.000 description 5
- 239000000080 wetting agent Substances 0.000 description 5
- VNDYJBBGRKZCSX-UHFFFAOYSA-L zinc bromide Chemical compound Br[Zn]Br VNDYJBBGRKZCSX-UHFFFAOYSA-L 0.000 description 5
- NYNZQNWKBKUAII-KBXCAEBGSA-N (3s)-n-[5-[(2r)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidin-3-yl]-3-hydroxypyrrolidine-1-carboxamide Chemical compound C1[C@@H](O)CCN1C(=O)NC1=C2N=C(N3[C@H](CCC3)C=3C(=CC=C(F)C=3)F)C=CN2N=C1 NYNZQNWKBKUAII-KBXCAEBGSA-N 0.000 description 4
- 125000006583 (C1-C3) haloalkyl group Chemical group 0.000 description 4
- BPXKZEMBEZGUAH-UHFFFAOYSA-N 2-(chloromethoxy)ethyl-trimethylsilane Chemical compound C[Si](C)(C)CCOCCl BPXKZEMBEZGUAH-UHFFFAOYSA-N 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- 101150117329 NTRK3 gene Proteins 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium on carbon Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
- 229960000583 acetic acid Drugs 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 4
- 239000003995 emulsifying agent Substances 0.000 description 4
- 230000004927 fusion Effects 0.000 description 4
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 4
- 229950003970 larotrectinib Drugs 0.000 description 4
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 229910000027 potassium carbonate Inorganic materials 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000010791 quenching Methods 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 4
- 235000019345 sodium thiosulphate Nutrition 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 239000000375 suspending agent Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 125000005958 tetrahydrothienyl group Chemical group 0.000 description 4
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 description 4
- OXJLDNSPGPBDCP-UHFFFAOYSA-N 1-(3,5-difluorophenyl)ethanone Chemical compound CC(=O)C1=CC(F)=CC(F)=C1 OXJLDNSPGPBDCP-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- 102100035080 BDNF/NT-3 growth factors receptor Human genes 0.000 description 3
- 102000008016 Eukaryotic Initiation Factor-3 Human genes 0.000 description 3
- 108010089790 Eukaryotic Initiation Factor-3 Proteins 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 101000596896 Homo sapiens BDNF/NT-3 growth factors receptor Proteins 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 3
- 101100348848 Mus musculus Notch4 gene Proteins 0.000 description 3
- 102100029166 NT-3 growth factor receptor Human genes 0.000 description 3
- 108010025020 Nerve Growth Factor Proteins 0.000 description 3
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 3
- 101000767160 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Intracellular protein transport protein USO1 Proteins 0.000 description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 3
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 229940041181 antineoplastic drug Drugs 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 125000003678 cyclohexadienyl group Chemical group C1(=CC=CCC1)* 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000006196 drop Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 3
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 201000002528 pancreatic cancer Diseases 0.000 description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 3
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 3
- 239000007909 solid dosage form Substances 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- JYUQEWCJWDGCRX-UHFFFAOYSA-N tert-butyl 4-formylpiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(C=O)CC1 JYUQEWCJWDGCRX-UHFFFAOYSA-N 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 2
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- HUUPVABNAQUEJW-UHFFFAOYSA-N 1-methylpiperidin-4-one Chemical compound CN1CCC(=O)CC1 HUUPVABNAQUEJW-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- NADOQPUIMDMEGD-UHFFFAOYSA-N 5-hydroxy-1-(oxan-2-yl)indazole-3-carbaldehyde Chemical compound N1=C(C=O)C2=CC(O)=CC=C2N1C1CCCCO1 NADOQPUIMDMEGD-UHFFFAOYSA-N 0.000 description 2
- 206010000599 Acromegaly Diseases 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 206010005003 Bladder cancer Diseases 0.000 description 2
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 2
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 2
- BUDQDWGNQVEFAC-UHFFFAOYSA-N Dihydropyran Chemical compound C1COC=CC1 BUDQDWGNQVEFAC-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 2
- 241000206672 Gelidium Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 239000007821 HATU Substances 0.000 description 2
- 101000996663 Homo sapiens Neurotrophin-4 Proteins 0.000 description 2
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 2
- 238000006751 Mitsunobu reaction Methods 0.000 description 2
- 101100317378 Mus musculus Wnt3 gene Proteins 0.000 description 2
- 102000015336 Nerve Growth Factor Human genes 0.000 description 2
- 102100033857 Neurotrophin-4 Human genes 0.000 description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- 208000017442 Retinal disease Diseases 0.000 description 2
- 206010038923 Retinopathy Diseases 0.000 description 2
- 208000000453 Skin Neoplasms Diseases 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 238000006859 Swern oxidation reaction Methods 0.000 description 2
- 208000024313 Testicular Neoplasms Diseases 0.000 description 2
- 206010057644 Testis cancer Diseases 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 2
- 208000002495 Uterine Neoplasms Diseases 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 208000009956 adenocarcinoma Diseases 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 235000012216 bentonite Nutrition 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- 125000002047 benzodioxolyl group Chemical group O1OC(C2=C1C=CC=C2)* 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 2
- 229910000024 caesium carbonate Inorganic materials 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000006482 condensation reaction Methods 0.000 description 2
- 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 2
- PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- 230000003831 deregulation Effects 0.000 description 2
- 229910052805 deuterium Inorganic materials 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 2
- 125000005057 dihydrothienyl group Chemical group S1C(CC=C1)* 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 201000004101 esophageal cancer Diseases 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 125000004438 haloalkoxy group Chemical group 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 125000002632 imidazolidinyl group Chemical group 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000003701 inert diluent Substances 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 2
- 125000003384 isochromanyl group Chemical group C1(OCCC2=CC=CC=C12)* 0.000 description 2
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- HAYYBYPASCDWEQ-UHFFFAOYSA-N n-[5-[(3,5-difluorophenyl)methyl]-1h-indazol-3-yl]-4-(4-methylpiperazin-1-yl)-2-(oxan-4-ylamino)benzamide Chemical compound C1CN(C)CCN1C(C=C1NC2CCOCC2)=CC=C1C(=O)NC(C1=C2)=NNC1=CC=C2CC1=CC(F)=CC(F)=C1 HAYYBYPASCDWEQ-UHFFFAOYSA-N 0.000 description 2
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 229940053128 nerve growth factor Drugs 0.000 description 2
- 230000000508 neurotrophic effect Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 125000000160 oxazolidinyl group Chemical group 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 125000004430 oxygen atom Chemical group O* 0.000 description 2
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 238000012877 positron emission topography Methods 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 2
- 125000003373 pyrazinyl group Chemical group 0.000 description 2
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 2
- 125000003226 pyrazolyl group Chemical group 0.000 description 2
- 125000002098 pyridazinyl group Chemical group 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- 125000000168 pyrrolyl group Chemical group 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 201000000849 skin cancer Diseases 0.000 description 2
- 208000000649 small cell carcinoma Diseases 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 235000010288 sodium nitrite Nutrition 0.000 description 2
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 201000003120 testicular cancer Diseases 0.000 description 2
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 2
- 125000001984 thiazolidinyl group Chemical group 0.000 description 2
- 125000000335 thiazolyl group Chemical group 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- PYOKUURKVVELLB-UHFFFAOYSA-N trimethyl orthoformate Chemical compound COC(OC)OC PYOKUURKVVELLB-UHFFFAOYSA-N 0.000 description 2
- 201000005112 urinary bladder cancer Diseases 0.000 description 2
- 206010046766 uterine cancer Diseases 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- BMQDAIUNAGXSKR-UHFFFAOYSA-N (3-hydroxy-2,3-dimethylbutan-2-yl)oxyboronic acid Chemical compound CC(C)(O)C(C)(C)OB(O)O BMQDAIUNAGXSKR-UHFFFAOYSA-N 0.000 description 1
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 description 1
- UVNPEUJXKZFWSJ-LMTQTHQJSA-N (R)-N-[(4S)-8-[6-amino-5-[(3,3-difluoro-2-oxo-1H-pyrrolo[2,3-b]pyridin-4-yl)sulfanyl]pyrazin-2-yl]-2-oxa-8-azaspiro[4.5]decan-4-yl]-2-methylpropane-2-sulfinamide Chemical compound CC(C)(C)[S@@](=O)N[C@@H]1COCC11CCN(CC1)c1cnc(Sc2ccnc3NC(=O)C(F)(F)c23)c(N)n1 UVNPEUJXKZFWSJ-LMTQTHQJSA-N 0.000 description 1
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- UEGDJZYKJPZJAA-UHFFFAOYSA-N 1-(3,5-difluorophenyl)ethanol Chemical compound CC(O)C1=CC(F)=CC(F)=C1 UEGDJZYKJPZJAA-UHFFFAOYSA-N 0.000 description 1
- KVSVNRFSKRFPIL-UHFFFAOYSA-N 1-(bromomethyl)-3,5-difluorobenzene Chemical compound FC1=CC(F)=CC(CBr)=C1 KVSVNRFSKRFPIL-UHFFFAOYSA-N 0.000 description 1
- BAUWRHPMUVYFOD-UHFFFAOYSA-N 1-methylpiperidin-4-ol Chemical compound CN1CCC(O)CC1 BAUWRHPMUVYFOD-UHFFFAOYSA-N 0.000 description 1
- 125000004484 1-methylpiperidin-4-yl group Chemical group CN1CCC(CC1)* 0.000 description 1
- HCKNAJXCHMACDN-UHFFFAOYSA-N 1-methylpiperidine-4-carboxylic acid Chemical compound CN1CCC(C(O)=O)CC1 HCKNAJXCHMACDN-UHFFFAOYSA-N 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- 125000001731 2-cyanoethyl group Chemical group [H]C([H])(*)C([H])([H])C#N 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- JNODDICFTDYODH-UHFFFAOYSA-N 2-hydroxytetrahydrofuran Chemical compound OC1CCCO1 JNODDICFTDYODH-UHFFFAOYSA-N 0.000 description 1
- 125000006022 2-methyl-2-propenyl group Chemical group 0.000 description 1
- 229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
- ASOFZHSTJHGQDT-UHFFFAOYSA-N 3,5-difluorobenzaldehyde Chemical compound FC1=CC(F)=CC(C=O)=C1 ASOFZHSTJHGQDT-UHFFFAOYSA-N 0.000 description 1
- 125000006288 3,5-difluorobenzyl group Chemical group [H]C1=C(F)C([H])=C(C([H])=C1F)C([H])([H])* 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- 125000006041 3-hexenyl group Chemical group 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- JVQIKJMSUIMUDI-UHFFFAOYSA-N 3-pyrroline Chemical compound C1NCC=C1 JVQIKJMSUIMUDI-UHFFFAOYSA-N 0.000 description 1
- WDBQJSCPCGTAFG-QHCPKHFHSA-N 4,4-difluoro-N-[(1S)-3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-pyridin-3-ylpropyl]cyclohexane-1-carboxamide Chemical compound FC1(CCC(CC1)C(=O)N[C@@H](CCN1CCC(CC1)N1C(=NN=C1C)C(C)C)C=1C=NC=CC=1)F WDBQJSCPCGTAFG-QHCPKHFHSA-N 0.000 description 1
- BWGRDBSNKQABCB-UHFFFAOYSA-N 4,4-difluoro-N-[3-[3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl]-1-thiophen-2-ylpropyl]cyclohexane-1-carboxamide Chemical compound CC(C)C1=NN=C(C)N1C1CC2CCC(C1)N2CCC(NC(=O)C1CCC(F)(F)CC1)C1=CC=CS1 BWGRDBSNKQABCB-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 1
- PQMISDVWAJEGJR-UHFFFAOYSA-N 5-bromo-1-(oxan-2-yl)indazole-3-carbaldehyde Chemical compound N1=C(C=O)C2=CC(Br)=CC=C2N1C1CCCCO1 PQMISDVWAJEGJR-UHFFFAOYSA-N 0.000 description 1
- VXWVFZFZYXOBTA-UHFFFAOYSA-N 5-bromo-1h-indole Chemical compound BrC1=CC=C2NC=CC2=C1 VXWVFZFZYXOBTA-UHFFFAOYSA-N 0.000 description 1
- ILGTYHMEQSSHFG-UHFFFAOYSA-N 5-bromo-2h-indazole-3-carbaldehyde Chemical compound C1=C(Br)C=CC2=NNC(C=O)=C21 ILGTYHMEQSSHFG-UHFFFAOYSA-N 0.000 description 1
- UCSFZORYXSAROS-UHFFFAOYSA-N 5-nitro-1-(oxan-2-yl)indazole-3-carbaldehyde Chemical compound N1=C(C=O)C2=CC([N+](=O)[O-])=CC=C2N1C1CCCCO1 UCSFZORYXSAROS-UHFFFAOYSA-N 0.000 description 1
- OZFPSOBLQZPIAV-UHFFFAOYSA-N 5-nitro-1h-indole Chemical compound [O-][N+](=O)C1=CC=C2NC=CC2=C1 OZFPSOBLQZPIAV-UHFFFAOYSA-N 0.000 description 1
- UVUPPLXBIXJRKD-UHFFFAOYSA-N 5-nitro-2h-indazole-3-carbaldehyde Chemical compound C1=C([N+](=O)[O-])C=CC2=NNC(C=O)=C21 UVUPPLXBIXJRKD-UHFFFAOYSA-N 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 208000002008 AIDS-Related Lymphoma Diseases 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 208000009746 Adult T-Cell Leukemia-Lymphoma Diseases 0.000 description 1
- 208000016683 Adult T-cell leukemia/lymphoma Diseases 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010061424 Anal cancer Diseases 0.000 description 1
- 208000007860 Anus Neoplasms Diseases 0.000 description 1
- 235000003276 Apios tuberosa Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000010744 Arachis villosulicarpa Nutrition 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- PIOZCCDVMFVBPG-UHFFFAOYSA-N CC(C1=CC(F)=CC(F)=C1)OC1=CC=C2N(C3OCCCC3)N=C(C=O)C2=C1 Chemical compound CC(C1=CC(F)=CC(F)=C1)OC1=CC=C2N(C3OCCCC3)N=C(C=O)C2=C1 PIOZCCDVMFVBPG-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010058019 Cancer Pain Diseases 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 206010007882 Cellulitis Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 208000023890 Complex Regional Pain Syndromes Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- DSLZVSRJTYRBFB-LLEIAEIESA-L D-glucarate(2-) Chemical compound [O-]C(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O DSLZVSRJTYRBFB-LLEIAEIESA-L 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 206010014967 Ependymoma Diseases 0.000 description 1
- 208000032027 Essential Thrombocythemia Diseases 0.000 description 1
- 208000006168 Ewing Sarcoma Diseases 0.000 description 1
- JNCMHMUGTWEVOZ-UHFFFAOYSA-N F[CH]F Chemical compound F[CH]F JNCMHMUGTWEVOZ-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010065390 Inflammatory pain Diseases 0.000 description 1
- 241000221089 Jatropha Species 0.000 description 1
- 208000022120 Jeavons syndrome Diseases 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 206010052178 Lymphocytic lymphoma Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000000172 Medulloblastoma Diseases 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 206010028391 Musculoskeletal Pain Diseases 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 description 1
- NUGPIZCTELGDOS-QHCPKHFHSA-N N-[(1S)-3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-pyridin-3-ylpropyl]cyclopentanecarboxamide Chemical compound C(C)(C)C1=NN=C(N1C1CCN(CC1)CC[C@@H](C=1C=NC=CC=1)NC(=O)C1CCCC1)C NUGPIZCTELGDOS-QHCPKHFHSA-N 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 101150111783 NTRK1 gene Proteins 0.000 description 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- 102000007072 Nerve Growth Factors Human genes 0.000 description 1
- 208000009277 Neuroectodermal Tumors Diseases 0.000 description 1
- 208000009905 Neurofibromatoses Diseases 0.000 description 1
- 102100029268 Neurotrophin-3 Human genes 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 101150056950 Ntrk2 gene Proteins 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000000821 Parathyroid Neoplasms Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- 208000007641 Pinealoma Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 208000004550 Postoperative Pain Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 1
- 102000052575 Proto-Oncogene Human genes 0.000 description 1
- 108700020978 Proto-Oncogene Proteins 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 201000008183 Pulmonary blastoma Diseases 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 108091005682 Receptor kinases Proteins 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- 206010058556 Serositis Diseases 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- SSZBUIDZHHWXNJ-UHFFFAOYSA-N Stearinsaeure-hexadecylester Natural products CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC SSZBUIDZHHWXNJ-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 1
- 229920002253 Tannate Polymers 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 102000005937 Tropomyosin Human genes 0.000 description 1
- 108010030743 Tropomyosin Proteins 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 208000017733 acquired polycythemia vera Diseases 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000005298 acute pain Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 201000006966 adult T-cell leukemia Diseases 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 206010064930 age-related macular degeneration Diseases 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 201000011165 anus cancer Diseases 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004622 benzoxazinyl group Chemical group O1NC(=CC2=C1C=CC=C2)* 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 208000003362 bronchogenic carcinoma Diseases 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- KVNRLNFWIYMESJ-UHFFFAOYSA-N butyronitrile Chemical compound CCCC#N KVNRLNFWIYMESJ-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- FATUQANACHZLRT-KMRXSBRUSA-L calcium glucoheptonate Chemical compound [Ca+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O FATUQANACHZLRT-KMRXSBRUSA-L 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 1
- 125000004976 cyclobutylene group Chemical group 0.000 description 1
- 125000004956 cyclohexylene group Chemical group 0.000 description 1
- 125000000522 cyclooctenyl group Chemical group C1(=CCCCCCC1)* 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000004979 cyclopentylene group Chemical group 0.000 description 1
- 125000004980 cyclopropylene group Chemical group 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 229940043237 diethanolamine Drugs 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 125000005433 dihydrobenzodioxinyl group Chemical group O1C(COC2=C1C=CC=C2)* 0.000 description 1
- 125000000723 dihydrobenzofuranyl group Chemical group O1C(CC2=C1C=CC=C2)* 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- 125000001070 dihydroindolyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- XHFGWHUWQXTGAT-UHFFFAOYSA-N dimethylamine hydrochloride Natural products CNC(C)C XHFGWHUWQXTGAT-UHFFFAOYSA-N 0.000 description 1
- IQDGSYLLQPDQDV-UHFFFAOYSA-N dimethylazanium;chloride Chemical compound Cl.CNC IQDGSYLLQPDQDV-UHFFFAOYSA-N 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- MYTMXVHNEWBFAL-UHFFFAOYSA-L dipotassium;carbonate;hydrate Chemical compound O.[K+].[K+].[O-]C([O-])=O MYTMXVHNEWBFAL-UHFFFAOYSA-L 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 238000003821 enantio-separation Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 229950000521 entrectinib Drugs 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-L ethane-1,2-disulfonate Chemical compound [O-]S(=O)(=O)CCS([O-])(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-L 0.000 description 1
- 229940031098 ethanolamine Drugs 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 229940093499 ethyl acetate Drugs 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 208000024519 eye neoplasm Diseases 0.000 description 1
- 239000003885 eye ointment Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- VUWZPRWSIVNGKG-UHFFFAOYSA-N fluoromethane Chemical compound F[CH2] VUWZPRWSIVNGKG-UHFFFAOYSA-N 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 201000010175 gallbladder cancer Diseases 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 229940097042 glucuronate Drugs 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 230000009033 hematopoietic malignancy Effects 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 210000003026 hypopharynx Anatomy 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 125000001841 imino group Chemical group [H]N=* 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 238000011645 inflammation animal model Methods 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 206010023841 laryngeal neoplasm Diseases 0.000 description 1
- 210000000088 lip Anatomy 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 201000011649 lymphoblastic lymphoma Diseases 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940091250 magnesium supplement Drugs 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 208000026045 malignant tumor of parathyroid gland Diseases 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- JZMJDSHXVKJFKW-UHFFFAOYSA-M methyl sulfate(1-) Chemical compound COS([O-])(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-M 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 125000001064 morpholinomethyl group Chemical group [H]C([H])(*)N1C([H])([H])C([H])([H])OC([H])([H])C1([H])[H] 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 201000005962 mycosis fungoides Diseases 0.000 description 1
- 206010028537 myelofibrosis Diseases 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 210000001989 nasopharynx Anatomy 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 230000002956 necrotizing effect Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000008692 neointimal formation Effects 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 201000004931 neurofibromatosis Diseases 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 208000021722 neuropathic pain Diseases 0.000 description 1
- 239000003900 neurotrophic factor Substances 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 201000008106 ocular cancer Diseases 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000003605 opacifier Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 210000003300 oropharynx Anatomy 0.000 description 1
- PXQPEWDEAKTCGB-UHFFFAOYSA-N orotic acid Chemical compound OC(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-N 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 125000005981 pentynyl group Chemical group 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 208000024724 pineal body neoplasm Diseases 0.000 description 1
- 208000037244 polycythemia vera Diseases 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 208000015768 polyposis Diseases 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229960003975 potassium Drugs 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical class [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 208000003476 primary myelofibrosis Diseases 0.000 description 1
- 208000029340 primitive neuroectodermal tumor Diseases 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 229960004063 propylene glycol Drugs 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 229940043131 pyroglutamate Drugs 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 125000003410 quininyl group Chemical group 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 201000002314 small intestine cancer Diseases 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229940083542 sodium Drugs 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000000967 suction filtration Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 208000006379 syphilis Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- DXICWTCECGHECU-UHFFFAOYSA-N tert-butyl 3-amino-4,4-diethoxypiperidine-1-carboxylate Chemical compound CCOC1(OCC)CCN(C(=O)OC(C)(C)C)CC1N DXICWTCECGHECU-UHFFFAOYSA-N 0.000 description 1
- NXZIGGBPLGAPTI-UHFFFAOYSA-N tert-butyl 6-oxa-3-azabicyclo[3.1.0]hexane-3-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CC2OC21 NXZIGGBPLGAPTI-UHFFFAOYSA-N 0.000 description 1
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 1
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 1
- 150000003527 tetrahydropyrans Chemical group 0.000 description 1
- 125000003507 tetrahydrothiofenyl group Chemical group 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000006208 topical dosage form Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 125000006168 tricyclic group Chemical group 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
- 229940102001 zinc bromide Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本申请涉及TRK激酶抑制剂化合物及其用途。具体地,本申请公开了如式(I)所示的化合物、或其同位素标记化合物、或其光学异构体、几何异构体、互变异构体或异构体混合物、或其药学上可接受的盐、或其前药、或其代谢物。本申请还涉及所述化合物在医学方面的应用。
Description
技术领域
本申请提供了一类具有药学活性的新颖化合物,所述化合物可用于抑制TRK激酶活性。本申请还涉及包含所述化合物的组合物,以及所述化合物和所述组合物在制备用于治疗与TRK激酶或NTRK基因相关的疾病或病症的药物中的用途。
背景技术
蛋白激酶(Protein Kinase,PK)为细胞生长、增殖和存活的关键调节因子,蛋白激酶的功能失常是许多疾病的标志。与人类癌症有关的致癌基因和原癌基因有一大部分编码PK。作为蛋白激酶的一种,TRK激酶(Tropomyosin receptor kinase,原肌球蛋白受体激酶)近年来引起人研究人员的注意。
TRK激酶属于隶属于受体酪氨酸激酶家族。Trk家族主要包括3个成员TRKA、TRKB和TRKC,其分别由神经营养受体酪氨酸激酶(Neurotrophic receptor tyrosine kinase,NTRK)基因:NTRK1基因、NTRK2基因、NTRK3基因编码。以往的研究证实,作为神经生长因子(NGF)、脑源性神经营养因子(BDNF)、神经营养因子4/5(NT-4/5)、以及神经营养因子3(NT-3)受体的这些TRK激酶可以调节神经元细胞的信号维持、神经元细胞的信号传导、细胞的增殖、分化、代谢、甚至凋亡。TRK激酶在人类恶性肿瘤中通过多种机制被组成性激活。最公认的机制是NTRK基因融合,其中3′NTRK基因区域在染色体内或染色体间重排,然后与5′融合伙伴基因的序列,导致肿瘤发生的高风险。TRK激酶的活化或失调、以及NTRK基因融合已经被证实与多种肿瘤或癌症的发生、发展和恶化密切相关;对于具有NTRK融合基因表达的患者,TRK是肿瘤治疗的重要靶点。因此,小分子TRK激酶抑制剂被认为是一种很有潜力的广谱抗癌药物。此外,已经证明TRK抑制剂在临床前疼痛动物模型和临床前炎症动物模型是有效的。
拉罗替尼(Larotrectinib),又称LOXO-101或Vitrakvi,是首个被批准上市的TRK抑制剂抗癌药物。其在一些癌症的治疗中已经显示出明显疗效,但是其价格极其昂贵,且长期服用后有难以克服的抗药性问题。第二个被批准上市的TRK抑制剂药物是恩曲替尼(Entrectinib),又称Rozlytrek,同样显示了良好的广谱抗癌活性。
拉罗替尼和恩曲替尼的成功使研究人员认识到了TRK抑制剂在癌症治疗中重要性和前景。但是,目前仍存在对于其他替代TRK抑制剂的迫切需求。
发明内容
在第一个方面,本申请提供了作为TRK激酶抑制剂的式(I)的化合物,
或其同位素标记化合物、或其光学异构体、几何异构体、互变异构体或异构体混合物、或其药学上可接受的盐、或其前药、或其代谢物,其中:
R1、R2各自独立地选自H、CN、C1-4烷基、C1-4卤代烷基、C1-4烷氧基和卤素;
R3选自H、C1-4烷基、C1-4卤代烷基、C1-4烷氧基、C3-6脂环基和4-6元杂脂环基;
R6的个数为1、2或3个,且每个R6各自独立地选自H、卤素、-CN、-OH、-NO2、-NR7R8、C1-4烷基、C1-4卤代烷基、C1-4烷氧基、C3-6脂环基和4-6元杂脂环基;
X为连接键、O、S或(NR4),其中R4选自:H、C1-4烷基、C1-4卤代烷基、C1-4烷氧基、C3-6脂环基和4-6元杂脂环基;
R7和R8各自独立地选自:H、C1-6烷基、C1-4卤代烷基、C1-4烷氧基,或者R7、R8以及与它们相连的N原子共同形成3-6元环;
n=1、2或3;
L为(C=O)、(O=S=O)、CRaRb或连接键,其中Ra和Rb各自独立地选自:H、C1-4烷基、C1-4卤代烷基、C1-4烷氧基、C3-6脂环基和4-6元杂脂环基,或者Ra、Rb以及与它们相连的碳原子共同形成3-6元环;
R5选自H、卤素、-OH、-NO2、-CN、-SF5、-SH、-S-C1-4烷基、C1-6烷基、C1-6卤代烷基、C1-6烷氧基、C1-6卤代烷氧基、C2-8烯基、C2-8炔基、C3-7脂环基、3-10元杂脂环基、C6-12双环脂环基、6-12元双环杂脂环基、C8-15元三环脂环基、8-15元三环杂脂环基、C5-8芳基、5-10元杂芳基、C7-11双环芳基、7-11元双环杂芳基、-C1-4烷基-(C3-7脂环基)、-C1-4烷基-(3-10元杂脂环基)、-C1-4烷基-(C6-12双环脂环基)、-C1-4烷基-(6-12元双环杂脂环基)、-C1-4烷基-(C8-15元三环脂环基)、-C1-4烷基-(8-15元三环杂脂环基)、-C1-4烷基-(C5-8芳基)、-C1-4烷基-(5-10元杂芳基)、-N(R10)(R11)、-N(R10)(C(=O)R11)、-N(R10)(C(=O)-OR11)、-N(R12)(C(=O)-N(R10)(R11))、-C(=O)-N(R10)(R11)、-C(=O)-R12、-C(=O)-OR12、-OC(=O)R12、-N(R10)(S(=O)2R11)、-S(=O)2-N(R10)(R11)、-SR12和-OR12,其中所述-S-C1-4烷基、C1-6烷基、C1-6烷氧基、C1-6卤代烷氧基、C2-8烯基、C2-8炔基、C3-7脂环基、3-10元杂脂环基、C6-12双环脂环基、6-12元双环杂脂环基,C8-15元三环脂环基、8-15元三环杂脂环基、C5-8芳基、5-7元杂芳基、C7-11双环芳基、7-11元双环杂芳基、-C1-4烷基-(C3-7脂环基)、-C1-4烷基-(3-10元杂脂环基)、-C1-4烷基-(C6-12双环脂环基)、-C1-4烷基-(6-12元双环杂脂环基)-C1-4烷基-(C8-15元三环脂环基)、-C1-4烷基-(8-15元三环杂脂环基)、-C1-4烷基-(C5-8芳基)和-C1-4烷基-(5-10元杂芳基)各自任选地被0、1、2、3或4个R5a取代,且R5a独立选自卤素、-OH、-NO2、-CN、-SF5、-SH、-S-C1-4烷基、氧代、C1-4烷基、C1-4卤代烷基、C1-4烷氧基、C1-4卤代烷氧基、C2-8烯基、C2-8炔基、C3-7脂环基、3-10元杂脂环基、C5-8芳基、5-7元杂芳基、-N(R13)(R14)、-N(R13)(C(=O)R14)、-N(R13)(C(=O)-OR14)、-N(R15)(C(=O)-N(R13)(R14))、-C(=O)-N(R13)(R14)、-C(=O)-R15、-C(=O)-OR15、-OC(=O)R15、-N(R13)(S(=O)2R14)、-S(=O)2-N(R13)(R14)、-SR15和-OR15;
且R10、R11、R12、R13、R14、和R15各自在每次出现时独立地选自:H、C1-6烷基、C1-6卤代烷基、C3-7脂环基、3-10元杂脂环基、C5-8芳基、5-7元杂芳基、C7-11双环芳基、7-11元双环杂芳基、-C1-4烷基-(C3-7脂环基)、-C1-4烷基-(3-10元杂脂环基)、-C1-4烷基-(C6-12双环脂环基)、-C1-4烷基-(6-12元双环杂脂环基)、-C1-4烷基-(C8-15元三环脂环基)、-C1-4烷基-(8-15元三环杂脂环基)、-C1-4烷基-(C5-8芳基)和-C1-4烷基-(5-10元杂芳基),其中该群组内的各个选项任选地被0、1、2、3或4个各自独立选自以下群组的取代基所取代:卤素、-OH、-NH2、-NH(CH3)、-N(CH3)2、-CN、-NO2、-SF5、-SH、-S-C1-4烷基、氧代、C1-4烷基、C2-6烯基、C2-6炔基、C3-7脂环基、3-10元杂脂环基、C5-8芳基、5-7元杂芳基、C7-11双环芳基、7-11元双环杂芳基、C1-4羟烷基、-S-C1-4烷基、-C(=O)H、-C(=O)-C1-4烷基、-C(=O)-O-C1-4烷基、-C(=O)-NH2、-C(=O)-N(C1-4烷基)2、C1-4卤代烷基、C1-4烷氧基和C1-4卤代烷氧基;或者R10、R11以及与它们相连的原子共同形成3-14元环;或者R13、R14以及与它们相连的原子共同形成3-14元环。
除非另有指明,本文所述的“式(I)所示的化合物”、“式(I)的化合物”或“本申请的化合物”或类似术语也涵盖其任意光学异构体、几何异构体、互变异构体或异构体的混合物。
术语“光学异构体”意指,当化合物具有一个或更多个手性中心时,每个手性中心可以存在R构型或S构型,由此构成的各种异构体为光学异构体。光学异构体包括所有的非对映异构体、对映异构体、内消旋体、外消旋体或其混合物形式。例如,通过手性色谱柱或通过手性合成可以分离光学异构体。
术语“几何异构体”意指,当化合物中存在双键时,该化合物可以存在顺式异构体、反式异构体、E型异构体和Z型异构体。几何异构体包括顺式异构体、反式异构体、E型异构体、Z型异构体或其混合物形式。
术语“互变异构体”指因分子中某一原子在两个位置迅速移动而产生的异构体。本领域技术人员可以理解:互变异构体之间可以互相转变,在在某一状态下可能会达到一种平衡状态而共存。
除非另有指明,本文所述的“式(I)所示的化合物”、“式(I)的化合物”或“本申请的化合物”等术语也涵盖该化合物中一个或者多个原子被其同位素原子代替而得到的同位素标记化合物。
适用于包含在本申请的化合物中的同位素的实例包括氢的同位素,诸如2H(D)和3H(T);碳的同位素,诸如11C、13C和14C;氯的同位素,诸如36Cl;氟的同位素,诸如18F;碘的同位素,诸如123I和125I;氮的同位素,诸如13N和15N;氧的同位素,诸如15O、17O和18O;以及硫的同位素,诸如35S。
所述同位素标记化合物(例如包含放射性同位素的那些)可用于药物和/或底物组织分布研究。考虑到引入的容易性和检测手段的方便性,放射性同位素氘(即D)和碳-14(即14C)对于该目的是特别有用的。
利用诸如氘(即D)的较重同位素进行取代可以提供某些治疗方面的益处并且因此在某些情况下可以是优选的,所述治疗方面的益处例如是由更大的代谢作用稳定性(例如,增长的体内半衰期或者减小的剂量要求)带来的。因此,在一些实施方式中,本申请的化合物是同位素标记化合物,其中H在每次出现时任选地被D取代。
利用正电子放射同位素(诸如11C、18F、15O和13N)进行取代可以用于正电子放射受体图像(Positron Emission Topography(PET))研究,用于检测底物受体占用状态。
所述同位素标记化合物一般可以通过本领域技术人员已知的常规技术或者通过使用合适的同位素标记试剂代替先前使用的非标记试剂来进行制备。
本申请的化合物可以以其药学上可接受的盐的形式存在。
术语“药学上可接受的”是指相应的化合物、载体或分子适于给予人。优选地,该术语是指由管理机构例如CFDA(中国)、EMEA(欧洲)、FDA(美国)等任意国家管理机构认证的用于哺乳动物优选人。
所述药学上可接受的盐类包括其酸加成盐和碱加成盐。适当的酸加成盐是由形成无毒性盐的酸所形成的。其实例包括但不限于:乙酸盐、己二酸盐、天冬氨酸盐、苯甲酸盐、苯磺酸盐、碳酸氢盐/碳酸盐、硫酸氢盐/硫酸盐、硼酸盐、樟脑磺酸盐、柠檬酸盐、环己胺磺酸盐、乙二磺酸盐、甲酸盐、反丁烯二酸盐、葡萄庚糖酸盐、葡萄糖酸盐、葡萄糖醛酸盐、六氟磷酸盐、2-(4-羟苄基)苯甲酸盐、氢氯化物/氯化物、氢溴化物/溴化物、氢碘化物/碘化物、2-羟乙磺酸盐、乳酸盐、苹果酸盐、顺丁烯二酸盐、丙二酸盐、甲磺酸盐、甲基硫酸盐、萘酸盐、2-萘磺酸盐、烟碱酸盐、硝酸盐、乳清酸盐、草酸盐、十六酸盐、磷酸盐/磷酸氢盐/磷酸二氢盐、焦谷氨酸盐、葡萄糖二酸盐、硬脂酸盐、水杨酸盐、单宁酸盐、酒石酸盐、甲苯磺酸盐和三氟乙酸盐。适当的碱加成盐是由形成无毒性盐的碱所形成的。其实例包括但不限于:铝、精氨酸、钙、胆碱、二乙胺、二乙醇胺、甘氨酸、赖氨酸、镁、葡甲胺、乙醇胺、钾、钠、氨丁三醇和锌盐。还可形成酸和碱的半盐,例如半硫酸盐和半钙盐。关于合适的盐的综述,参见Handbook of Pharmaceutical Salts:Properties,Selection and Use by Stahl andWermuth(Wiley-VCH,2002)。用于制备本文中所述的化合物的药学上可接受的盐的方法是本领域技术人员已知的。
此外,本申请化合物可以以非溶剂化形式以及与药学上可接受的溶剂如水、乙醇等的溶剂化形式存在。化合物也可以以一种或多种结晶状态存在,即多晶型,或者它们可以作为无定形固体存在。所有这些形式都包含在本申请的范围内。
本申请还包括本申请的化合物的前药。术语“前药”是指通过与酶、胃酸等在生理条件下在活体内例如通过各自在酶催化下进行的氧化、还原、水解等反应转化为本申请化合物的衍生物。因此,本申请化合物的某些衍生物本身可能具有很少或没有药理学活性,当给药至体内或身体上时,可以转化成具有所需活性的本申请化合物。
本申请还包括本申请的化合物的代谢物。术语“代谢物”是指在细胞或有机体优选人中源自本申请任意化合物的所有分子。
在本文中使用时,术语“被取代”是指基团中的一个或多个(优选1至5个,更优选1至3个)氢原子独立地被相应数目的取代基所代替。
在本文中使用时,术语“独立地”是指当取代基的个数超过一个时,这些取代基可以相同也可以不同。
在本文中使用时,术语“任选”或“任选地”表示其所描述的事件可以发生或不发生。例如,一个基团“任选地被取代”表示:该基团可以是未被取代的,也可以是被取代的。
术语“卤素”或“卤”是指-F,-Cl,-Br,或-I。
在本文中使用时,术语“烷基”是指饱和的脂族烃,包括直链及支链。在一些实施方式中,烷基基团具有1-8个、或1-6个、或1-4个、或1-3个碳原子。例如,术语“C1-8烷基”是指具有1-8个碳原子的直链或支链原子团。术语“C1-8烷基”在其定义中包括术语“C1-6烷基”、“C1-3烷基”和“C1-4烷基”等。烷基的实例包括但不限于甲基、乙基、丙基、异丙基、丁基、异丁基、仲丁基、叔丁基、戊基、2-戊基、3-戊基、异戊基、新戊基、(R)-2-甲基丁基、(S)-2-甲基丁基、3-甲基丁基、2,3-二甲基丙基、2,3-二甲基丁基、己基等。烷基基团可任选地被一或多个(例如,1至5个)适当的取代基所取代。
在本文中使用时,术语“烯基”是指具有至少一个碳-碳双键的脂族烃,包括具有至少一个碳-碳双键的直链及支链。在一些实施方式中,烯基基团具有2-8个碳原子、2-6个碳原子、3-6个碳原子、或2-4个碳原子。例如,术语“C2-8烯基”是指具有2-8个碳原子的直链或支链的不饱和原子团(具有至少一个碳-碳双键)。所述双键可以是或者可以不是另一基团的连接点。烯基包括但不限于乙烯基、1-丙烯基、2-丙烯基、2-甲基-2-丙烯基、丁烯基、戊烯基、3-己烯基等。烯基基团可任选地被一或多个(例如,1至5个)适当的取代基所取代。当式(I)的化合物含有烯基基团时,该烯基基团可以纯E形式、纯Z形式、或其任何混合物存在。
在本文中使用时,术语“炔基”是指具有至少一个碳-碳三键的脂族烃,包括具有至少一个碳-碳三键的直链及支链。在一些实施方式中,炔基基团具有2-8个碳原子、2-6个碳原子、3-6个碳原子、或2-4个碳原子。例如,术语“C2-8炔基”是指具有2-8个碳原子的直链或支链的不饱和原子团(具有至少一个碳-碳三键)。所述三键可以是或者可以不是另一基团的连接点。炔基包括但不限于乙炔基、1-丙炔基、2-丙炔基、2-甲基-2-丙炔基、丁炔基、戊炔基、3-己炔基等。炔基基团可任选地被一或多个(例如,1至5个)适当的取代基所取代。
在本文中使用时,术语“C3-8脂环基”是指具有3-8个形成环的碳原子的脂环基。术语“C3-7脂环基”是指具有3-7个形成环的碳原子的脂环基。术语“C3-6脂环基”是指具有3-6个形成环的碳原子的脂环基。所述脂环基可以是单环环。脂环基的定义还包括不饱和的非芳族脂环基。脂环基的实例为,例如环丙基、环丁基、环戊基、环己基、环己烯基、环庚基、环辛基、环己二烯基、环戊烯基、环庚烯基和环辛烯基。脂环基可任选地被一或多个适当的取代基所取代。
本文中使用时,术语“C6-12双环脂环基”是具有6-12个形成环的碳原子的含有两个环的脂环基。双环脂环基可稠合,也可包括桥连双环脂环基系统。
本文中使用时,术语“C8-15元三环脂环基”是具有8-15个形成环的碳原子的含有三个环的脂环基。三环脂环基可稠合,也可桥连。
在本文中使用时,术语“n元杂脂环基”是指具有m个形成环的碳原子和(n-m)个形成环的杂原子的脂环基,所述杂原子选自O、S及N。例如,术语“4-8元杂脂环基”是指杂脂环基取代基含有总共4至8个环原子,其中至少一个是杂原子;术语“4-6元杂脂环基”是指杂脂环基取代基含有总共4至6个环原子,其中至少一个是杂原子;术语“3-10元杂脂环基”是指杂脂环基取代基含有总共3至10个环原子,其中至少一个是杂原子。术语“n元双环杂脂环基”是指具有m个形成环的碳原子和(n-m)个形成环的杂原子的双环杂脂环基,所述杂原子选自O、S及N。杂脂环基的实例包括,但不限于,氮杂环丁烷基、硫杂环丁烷基、二氢呋喃基、二氢噻吩基、四氢噻吩基、四氢呋喃基、四氢三嗪基、四氢吡唑基、四氢噁嗪基、四氢嘧啶基、八氢苯并呋喃基、八氢苯并咪唑基、八氢苯并噻唑基、咪唑烷基、吡咯烷基、哌啶基、哌嗪基、噁唑烷基、噻唑烷基、吡唑烷基、硫代吗啉基、四氢吡喃基、四氢噻喃基、四氢噻嗪基、四氢噻二嗪基、四氢噁唑基、吗啉基、氧杂环丁烷基、四氢二嗪基、噁嗪基、氧杂噻嗪基、奎宁环基、苯并二氢吡喃基(chromanyl)、异苯并二氢吡喃基(isochromanyl)、二氢苯并二噁英基(dihydrobenzodioxinyl)、苯并二氧杂环戊烯基(benzodioxolyl)、苯并噁嗪基、二氢吲哚基、二氢苯并呋喃基、四氢喹啉基、异色满基(isochromyl)、二氢-1H-异吲哚基、2-氮杂双环[2.2.1]庚酰基、3-氮杂双环[3.1.0]己基、3-氮杂双环[4.1.0]庚基、氧杂环庚烷基、硫杂环庚烷基、氮杂环庚烷基等。杂脂环基可任选地被一或多个适当的取代基所取代。
在本文中使用时,术语“C5-8芳基”是指具有含5-8个碳原子的芳环的芳基,例如苯基。
在本文中使用时,术语“n元杂芳基”是指具有m个形成芳环的碳原子和(n-m)个形成芳环的杂原子的杂芳基,所述杂原子选自O、S及N。例如,5-7元杂芳基包括但不限于呋喃基、噻吩基、吡咯基、噻唑基、吡唑基、咪唑基、吡啶基、吡喃基、哒嗪基、嘧啶基、吡嗪基。杂芳基可任选地被一或多个适当的取代基所取代。
在本文中使用时,术语“C7-11双环芳基”是指具有7-11个碳原子的双环芳基,例如萘基、茚基等。双环芳基可任选地被一或多个适当的取代基所取代。
在本文中使用时,术语“n元双环杂芳基”是指具有m个形成芳族双环的碳原子和(n-m)个形成芳族双环的杂原子的双环杂芳基,所述杂原子选自O、S及N。例如,7-11元双环杂芳基包括但不限于喹啉基、异喹啉基、吲哚基、嘌呤基、苯并噻唑基等。双环杂芳基可任选地被一或多个适当的取代基所取代。
在本文中使用时,术语“11-15元三环基”包括但不限于吖啶基等。11-15元三环基可任选地被一或多个适当的取代基所取代。
在本文中使用时,术语“卤代烷基”是指具有一或多个卤素取代基的烷基基团(至多全卤代烷基,即,烷基基团的每个氢原子均被卤素原子所取代)。例如,术语“C1-6卤代烷基”是指具有一或多个卤素取代基的C1-6烷基基团(至多全卤代烷基,即,烷基基团的每个氢原子均被卤素原子所取代)。另举一例,术语“C1-4卤代烷基”是指具有一或多个卤素取代基的C1-4烷基基团(至多全卤代烷基,即,烷基基团的每个氢原子均被卤素原子所取代);术语“C1-3卤代烷基”是指具有一或多个卤素取代基的C1-3烷基基团(至多全卤代烷基,即,烷基基团的每个氢原子均被卤素原子所取代);且术语“C1-2卤代烷基”是指具有一或多个卤素取代基的C1-2烷基基团(即,甲基或乙基)(至多全卤代烷基,即,烷基基团的每个氢原子均被卤素原子所取代)。再另举一例,术语“C1卤代烷基”是指具有1、2或3个卤素取代基的甲基基团。卤代烷基基团的例子包括:CF3、C2F5、CHF2、CH2F、CH2CF3、CH2Cl等。
在本文中使用时,术语“烷氧基”是指单键连接至氧原子的烷基。烷氧基与分子的连接点是通过氧原子。烷氧基可被描述为烷基-O-。术语“C1-6烷氧基”是指包含1-6个碳原子的直链或支链的烷氧基。术语“C1-6烷氧基”在其定义中包括术语“C1-3烷氧基”。烷氧基包括但不限于甲氧基、乙氧基、丙氧基、异丙氧基、丁氧基、己氧基等。烷氧基可任选地被一或多个适当的取代基所取代。
在本文中使用时,术语“3-14元环”是指具有3-14个成环原子的饱和或不饱和环体系。类似地,术语“3-6元环”是指具有3-6个成环原子的饱和或不饱和环体系,术语“3-8元环”是指具有3-8个成环原子的饱和或不饱和环体系。
本文中,与取代基个数、碳原子个数、环原子个数相关的数目范围表示该范围内所有整数的逐个列举,而范围仅是作为一种简化的表示法。例如:“4-6元”表示4、5或6元;“5-7元”表示5、6或7元;“7-11元”表示7、8、9、10或11元;“4-8元”表示4、5、6、7或8元;“3-10元”表示3、4、5、6、7、8、9或10元;“3-14元”表示3、4、5、6、7、8、9、10、11、12、13或14元;“C1-3”表示1个(C1)、2个(C2)或3个碳原子(C3);“C1-4”表示1个(C1)、2个(C2)、3个碳原子(C3)或4个碳原子(C4);“C3-6”表示3个(C3)、4个(C4)、5个(C5)或6个碳原子(C6);“C3-8”表示3个(C3)、4个(C4)、5个(C5)、6个(C6)、7个(C7)或8个碳原子(C8);“C5-7”表示5个(C5)、6个(C6)或7个碳原子(C7);“C7-11”表示7个(C7)、8个(C8)、9个(C9)、10个(C10)或11个碳原子(C11)。因此,与取代基个数、碳原子个数、环原子个数相关的数目范围也涵盖其任意一个子范围,且每一个子范围也视为被本文公开。
在如上所述的式(I)中,R1选自H、CN、C1-4烷基、C1-4卤代烷基、C1-4烷氧基和卤素。
在一些实施方式中,R1为H。
在一些实施方式中,R1为卤素,例如R1选自F、Cl、Br、I。
在一些实施方式中,R1为C1-4烷基或C1-4卤代烷基,例如任选地被任选地被一个或多个卤素原子(例如氟、氯、溴、碘)取代的甲基、乙基、丙基、异丙基、正丁基、异丁基。
在一些实施方式中,R1为C1-4烷氧基,例如甲氧基、乙氧基、丙氧基、异丙氧基、正丁氧基、异丁氧基。
在一些实施方式中,R1为CN。
应当理解,任何上述R1的实施方式可以与如上文和下文所述的任何R2、R3、R5、R6、X、L和n的实施方式以任意方式组合在一起。
在如上所述的式(I)中,R2选自H、CN、C1-4烷基、C1-4卤代烷基、C1-4烷氧基和卤素。
在一些实施方式中,R2为H。
在一些实施方式中,R2为卤素,例如R2选自F、Cl、Br、I。
在一些实施方式中,R2为C1-4烷基或C1-4卤代烷基,例如任选地被任选地被一个或多个卤素原子(例如氟、氯、溴、碘)取代的甲基、乙基、丙基、异丙基、正丁基、异丁基。
在一些实施方式中,R2为C1-4烷氧基,例如甲氧基、乙氧基、丙氧基、异丙氧基、正丁氧基、异丁氧基。
在一些实施方式中,R2为CN。
应当理解,任何上述R2的实施方式可以与如上文和下文所述的任何R1、R3、R5、R6、X、L和n的实施方式以任意方式组合在一起。
在一些实施方式中,R1和R2可以是相同的。例如,R1和R2均为卤素,例如Cl或F;再例如,R1和R2均为H。在一个优选的实施方式中,R1和R2均为F。在一个优选的实施方式中,R1和R2均为H。
在另一些实施方式中,R1和R2可以是不同的。
在如上所述的式(I)中,R3选自H、C1-4烷基、C1-4卤代烷基、C1-4烷氧基、C3-6脂环基和4-6元杂脂环基。
在一些实施方式中,R3为H。
在一些实施方式中,R3为C1-3烷基或C1-3卤代烷基,例如,R3选自任选地被一个或多个卤素原子(例如氟、氯、溴、碘)取代的甲基、乙基、丙基、异丙基。
在一些实施方式中,R3为C1-3烷氧基,例如,R3选自甲氧基、乙氧基、丙氧基、异丙氧基。
在一些实施方式中,R3为C3-6脂环基,例如,R3选自环丙基、环丁基、环戊基、环己基、环己烯基、环己二烯基、环戊烯基等。
在一些实施方式中,R3为4-6元杂脂环基,杂原子可以选自O、S及N。例如,R3选自氧杂环丁烷基、硫杂环丁烷基、氮杂环丁烷基、四氢呋喃基、四氢噻吩基、吡咯烷基、四氢吡喃基、四氢噻喃基、哌啶基、吗啉基、哌嗪基。
在一些实施方式中,R3为甲基。
应当理解,任何上述R3的实施方式可以与如上文和下文所述的任何R1、R2、R5、R6、X、L和n的实施方式以任意方式组合在一起。
在如上所述的式(I)中,R6的个数可以为1、2或3个,其中每个R6各自独立地选自H、卤素、-CN、-OH、-NO2、-NR7R8、C1-4烷基、C1-4卤代烷基、C1-4烷氧基、C3-6脂环基和4-6元杂脂环基(杂原子可以选自O、S及N),其中R7和R8各自独立地选自:H、C1-6烷基、C1-4卤代烷基、C1-4烷氧基;或者R7、R8以及与它们相连的N原子共同形成3-6元环,例如此时R7、R8均为(CH2)n(n=1、2、3、4、5等)或R7、R8以及与它们相连的N原子共同构成5元或6元含N芳香环。
在一些优选的实施方式中,R6为H。
在一些实施方式中,R6为卤素,例如R6选自F、Cl、Br、I。
在一些实施方式中,R6为-CN、-OH或-NO2。
在一些实施方式中,R6为C1-3烷基或C1-3卤代烷基,例如R6选自任选地被一个或多个卤素原子(例如氟、氯、溴、碘)取代的甲基、乙基、丙基、异丙基。
在一些实施方式中,R6为C1-3烷氧基,例如R6选自甲氧基、乙氧基、丙氧基、异丙氧基。
在一些实施方式中,R6为C3-6脂环基,例如R6选自环丙基、环丁基、环戊基、环己基、环己烯基。
在一些实施方式中,R6为4-6元杂脂环基(杂原子可以选自O、S及N),例如R6选自氧杂环丁烷基、硫杂环丁烷基、氮杂环丁烷基、四氢呋喃基、四氢噻吩基、吡咯烷基、四氢吡喃基、四氢噻喃基、哌啶基、吗啉基、哌嗪基。
在一些实施方式中,R6为-NR7R8,其中R7和R8各自独立地选自:H、C1-3烷基(例如甲基、乙基、丙基、异丙基等)、C1-3卤代烷基(例如被被一个或多个选自氟、氯、溴、碘的卤原子取代的甲基、乙基、丙基、异丙基)、C1-3烷氧基(例如甲氧基、乙氧基、丙氧基、异丙氧基);或者R7、R8以及与它们相连的N原子共同形成3-6元环,例如此时R7、R8均为(CH2)n(n=1、2、3、4、5等)或R7、R8以及与它们相连的N原子共同构成5元或6元含N芳香环,例如形成为吡咯、吡啶、嘧啶、咪唑、吡唑、吡咯烷、六氢吡啶等。
在一些实施方式中,R6为二甲氨基、二乙氨基、甲基乙基氨基。
在一些优选的实施方式中,R6为1个。
应当理解,任何上述R6的实施方式可以与如上文和下文所述的任何R1、R2、R3、R5、X、L和n的的实施方式以任意方式组合在一起。
在如上所述的式(I)中,X为连接键、O、S或(NR4),其中R4选自:H、C1-4烷基、C1-4卤代烷基、C1-4烷氧基、C3-6脂环基和4-6元杂脂环基(杂原子可以选自O、S及N)。
在一些实施方式中,X为连接键(即X不存在,此时X两侧的化学基团直接相连)。
在一些实施方式中,X为-O-。
在一些实施方式中,X为-S-。
在一些实施方式中,X为亚氨基,即-(NH)-。
在一些实施方式中,X为-(N(CH3))-。
在一些优选实施方式中,X选自连接键、-O-和-(NH)-。
应当理解,任何上述X的实施方式可以与如上文和下文所述的任何R1、R2、R3、R5、R6、L和n的的实施方式以任意方式组合在一起。
在如上所述的式(I)中,n为1、2或3。
在一些实施方式中,n为1。
在一些实施方式中,n为2。
在一些实施方式中,n为3。
应当理解,任何上述n的实施方式可以与如上文和下文所述的任何R1、R2、R3、R5、R6、L和X的的实施方式以任意方式组合在一起。
在如上所述的式(I)中,L为(C=O)、(O=S=O)、CRaRb或连接键,其中Ra和Rb各自独立地选自:H、C1-4烷基、C1-4卤代烷基、C1-4烷氧基、C3-6脂环基和4-6元杂脂环基(杂原子可以选自O、S及N),或者Ra、Rb以及与它们相连的碳原子共同形成3-6元环,例如此时Ra、Rb均为(CH2)n(n=1、2、3、4、5等)从而形成3-6元饱和脂环或Ra、Rb以及与它们相连的C原子共同构成3-6元不饱和脂环或6元芳香环。
在一些实施方式中,L为-(C=O)-。
在一些实施方式中,L为-(O=S=O)-。
在一些实施方式中,L为连接键(即L不存在,此时R5与N直接相连)。
在一些实施方式中,L为-(CRaRb)-,其中Ra和Rb各自独立地选自:H、C1-4烷基(例如甲基、乙基、丙基、异丙基、正丁基、异丁基、叔丁基等)、C1-4卤代烷基(例如被被一个或多个选自氟、氯、溴、碘的卤原子取代的甲基、乙基、丙基、异丙基、正丁基、异丁基、叔丁基等)、C1-4烷氧基(例如甲氧基、乙氧基、丙氧基、异丙氧基、正丁氧基、异丁氧基、叔丁氧基等)、C3-6脂环基(例如环丙基、环丁基、环戊基、环己基、环己烯基、环己二烯基、环戊烯基等)和4-6元杂脂环基(例如氧杂环丁烷基、硫杂环丁烷基、氮杂环丁烷基、四氢呋喃基、四氢噻吩基、吡咯烷基、四氢吡喃基、四氢噻喃基、哌啶基、吗啉基、哌嗪基等),或者Ra、Rb以及与它们相连的碳原子共同形成3-6元环(优选3-6元脂环族环)。例如,L可以为-CH2-、-C(CH3)2-、-CH(CH3)-、亚环丙基、亚环丁基、亚环戊基、亚环己基、亚苯基等等。
应当理解,任何上述L的实施方式可以与如上文和下文所述的任何R1、R2、R3、R5、R6、n和X的的实施方式以任意方式组合在一起。
在如上所述的式(I)中,R5可以是有机化学中常见的任何取代基,其并不特别受限。
在一些实施方式中,R5为C1-6烷基,例如R5选自甲基、乙基、丙基、异丙基、丁基、异丁基、仲丁基、叔丁基、戊基、2-戊基、3-戊基、异戊基、新戊基、(R)-2-甲基丁基、(S)-2-甲基丁基、3-甲基丁基、2,3-二甲基丙基、2,3-二甲基丁基、己基。
在一些实施方式中,R5为C3-7脂环基,例如R5选自环丙基、环丁基、环戊基、环己基、环己烯基、环庚基、环己二烯基、环戊烯基、环庚烯基。
在一些实施方式中,R5为3-10元杂脂环基,例如R5选自氮杂环丁烷基、硫杂环丁烷基、二氢呋喃基、二氢噻吩基、四氢噻吩基、四氢呋喃基、四氢三嗪基、四氢吡唑基、四氢噁嗪基、四氢嘧啶基、八氢苯并呋喃基、八氢苯并咪唑基、八氢苯并噻唑基、咪唑烷基、吡咯烷基、哌啶基、哌嗪基、噁唑烷基、噻唑烷基、吡唑烷基、硫代吗啉基、四氢吡喃基、四氢噻喃基、四氢噻嗪基、四氢噻二嗪基、四氢噁唑基、吗啉基、氧杂环丁烷基、四氢二嗪基、噁嗪基、氧杂噻嗪基、奎宁环基、苯并二氢吡喃基、异苯并二氢吡喃基、二氢苯并二噁英基、苯并二氧杂环戊烯基、苯并噁嗪基、二氢吲哚基、二氢苯并呋喃基、四氢喹啉基、异色满基、二氢-1H-异吲哚基、氧杂环庚烷基、硫杂环庚烷基、氮杂环庚烷基。
在一些实施方式中,R5为H、卤素、-OH、-NO2、-CN、-SF5或-SH。
在一些实施方式中,R5选自-S-C1-4烷基、C1-6烷基、C1-6卤代烷基、C1-6烷氧基、C1-6卤代烷氧基、C2-8烯基、C2-8炔基。
在一些实施方式中,R5选自C5-8芳基(例如苯基)、5-10元杂芳基(例如呋喃基、噻吩基、吡咯基、噻唑基、吡唑基、咪唑基、吡啶基、吡喃基、哒嗪基、嘧啶基、吡嗪基等)、-C1-4烷基-(C5-8芳基)、-C1-4烷基-(5-10元杂芳基)。
在一些实施方式中,R5选自-N(R10)(R11)、-N(R10)(C(=O)R11)、-N(R10)(C(=O)-OR11)、-N(R12)(C(=O)-N(R10)(R11))、-C(=O)-N(R10)(R11)、-C(=O)-R12、-C(=O)-OR12、-OC(=O)R12、-N(R10)(S(=O)2R11)、-S(=O)2-N(R10)(R11)、-SR12和-OR12,其中R10、R11、R12各自在每次出现时独立地选自:H、C1-6烷基、C1-6卤代烷基、C3-7脂环基、3-10元杂脂环基、C5-8芳基、5-7元杂芳基、C7-11双环芳基、7-11元双环杂芳基、-C1-4烷基-(C3-7脂环基)、-C1-4烷基-(3-10元杂脂环基)、-C1-4烷基-(C6-12双环脂环基)、-C1-4烷基-(6-12元双环杂脂环基)、-C1-4烷基-(C8-15元三环脂环基)、-C1-4烷基-(8-15元三环杂脂环基)、-C1-4烷基-(C5-8芳基)和-C1-4烷基-(5-10元杂芳基),其中该群组内的各个选项任选地被0、1、2、3或4个各自独立选自以下群组的取代基所取代:卤素、-OH、-NH2、-NH(CH3)、-N(CH3)2、-CN、-NO2、-SF5、-SH、-S-C1-4烷基、氧代、C1-4烷基、C2-6烯基、C2-6炔基、C3-7脂环基、3-10元杂脂环基、C5-8芳基、5-7元杂芳基、C7-11双环芳基、7-11元双环杂芳基、C1-4羟烷基、-S-C1-4烷基、-C(=O)H、-C(=O)-C1-4烷基、-C(=O)-O-C1-4烷基、-C(=O)-NH2、-C(=O)-N(C1-4烷基)2、C1-4卤代烷基、C1-4烷氧基和C1-4卤代烷氧基;或者R10、R11以及与它们相连的原子共同形成3-14元环(例如,R10、R11均为(CH2)n(n=1、2、3、4、5、6、7、8等)或R10、R11以及与它们相连的原子共同构成5至14元芳香环)。
上述对于R5列举的任意示例基团都应被理解为是任选地被取代的;即在适当的时候,上述对于R5给出的任意基团可以任选地被0、1、2、3或4个R5a取代,且R5a独立选自卤素、-OH、-NO2、-CN、-SF5、-SH、-S-C1-4烷基、氧代、C1-4烷基、C1-4卤代烷基、C1-4烷氧基、C1-4卤代烷氧基、C2-8烯基、C2-8炔基、C3-7脂环基、3-10元杂脂环基、C5-8芳基、5-7元杂芳基、-N(R13)(R14)、-N(R13)(C(=O)R14)、-N(R13)(C(=O)-OR14)、-N(R15)(C(=O)-N(R13)(R14))、-C(=O)-N(R13)(R14)、-C(=O)-R15、-C(=O)-OR15、-OC(=
O)R15、-N(R13)(S(=O)2R14)、-S(=O)2-N(R13)(R14)、-SR15和-OR15,其中R13、R14、和R15各自在每次出现时独立地选自:H、C1-6烷基、C1-6卤代烷基、C3-7脂环基、3-10元杂脂环基、C5-8芳基、5-7元杂芳基、C7-11双环芳基、7-11元双环杂芳基、-C1-4烷基-(C3-7脂环基)、-C1-4烷基-(3-10元杂脂环基)、-C1-4烷基-(C6-12双环脂环基)、-C1-4烷基-(6-12元双环杂脂环基)、-C1-4烷基-(C8-15元三环脂环基)、-C1-4烷基-(8-15元三环杂脂环基)、-C1-4烷基-(C5-8芳基)和-C1-4烷基-(5-10元杂芳基),其中该群组内的各个选项任选地被0、1、2、3或4个各自独立选自以下群组的取代基所取代:卤素、-OH、-NH2、-NH(CH3)、-N(CH3)2、-CN、-NO2、-SF5、-SH、-S-C1-4烷基、氧代、C1-4烷基、C2-6烯基、C2-6炔基、C3-7脂环基、3-10元杂脂环基、C5-8芳基、5-7元杂芳基、C7-11双环芳基、7-11元双环杂芳基、C1-4羟烷基、-S-C1-4烷基、-C(=O)H、-C(=O)-C1-4烷基、-C(=O)-O-C1-4烷基、-C(=O)-NH2、-C(=O)-N(C1-4烷基)2、C1-4卤代烷基、C1-4烷氧基和C1-4卤代烷氧基;或者R13、R14以及与它们相连的原子共同形成3-14元环(例如,R13、R14均为(CH2)n(n=1、2、3、4、5、6、7、8等)或R13、R14以及与它们相连的原子共同构成5至14元芳香环)。
在一些优选的实施方式中,R5选自甲基、乙基、丙基、异丙基、环丁基基团。所述甲基、乙基、丙基、异丙基或环丁基基团可以任选地被0、1或2个各自独立选自以下群组的取代基所取代:甲基、乙基、环戊基、环丙基、-CN、-OH、吗啉基、哌啶基,所述取代基又可以任选地被0、1或2个各自独立选自以下群组的取代基所取代:甲基、乙基、环戊基、环丙基、-CN、-OH。例如,在一些优选的实施方式中,R5选自(1-羟基环丙基)乙基、3-羟基环丁基、2-氰基乙基、2-羟乙基、2-氰基-1-环戊基乙基、1-氰基丙烷、2-吗啉代乙基、乙基和(1-甲基哌啶-4-基)甲基。
在一些优选的实施方式中,R5选自卤素,例如F。
在一些优选的实施方式中,R5选自哌嗪基、吗啉基、吡咯烷基、哌啶基和氮杂环丁烷基,所述哌嗪基、吗啉基、吡咯烷基、哌啶基和氮杂环丁烷基可以任选地被0、1或2个各自独立选自以下群组的取代基所取代:甲基、乙基、环戊基、环丙基、-CN、-OH。在一些优选的实施方式中,R5选自甲基、乙基、丙基、异丙基、环丁基基团,所述甲基、乙基、丙基、异丙基或环丁基基团可以任选地被0、1或2个各自独立选自以下群组的取代基所取代:甲基、乙基、环戊基、环丙基、-CN、-OH、吗啉基、哌啶基,所述取代基又可以任选地被0、1或2个各自独立选自以下群组的取代基所取代:甲基、乙基、环戊基、环丙基、-CN、-OH。
在一些优选的实施方式中,R5选自哌嗪基、吗啉基、吡咯烷基、哌啶基、氮杂环丁烷基。例如,在一些优选的实施方式中,R5选自3,5-二甲基哌嗪基、吗啉基、3-羟基吡咯烷基、4-甲基哌嗪基、4-乙基哌嗪基、4-羟基哌啶基、1-甲基哌啶基、1-乙基哌啶-4-基、1-甲基氮杂环丁烷-3-基。
在一些优选的实施方式中,R5选自H、甲基、乙基、正丙基、异丙基、丁基、甲氧基、乙氧基、羟基、环丙基、环丁基、环戊基、环己基、吗啉代甲基、羟基环丁基、羟基环己基、氰基乙氧基、氰基甲基、吡啶-3-基、1-甲基-1H-吡唑-4-基、1-甲基-1H-吡唑-3-基、4-甲基哌嗪-1-基、1-甲基哌啶-4-基、吗啉基、吡咯烷-3-基、3-羟基吡咯烷-1-基、3-氰基吡咯烷-1-基。
应当理解,任何上述R5的实施方式可以与如上文和下文所述的任何R1、R2、R3、R6、X、L和n的实施方式以任意方式组合在一起。
在一些优选的实施方式中,本申请还涉及式(Ia)所示的化合物:
其中,X为-O-或-(NH)-;L、n、R3、R5、R6的定义以及优选项与式(I)化合物相同。
在一些优选的实施方式中,本申请还涉及式(Ib)所示的化合物:
其中,L、n、R5、R6的定义以及优选项与式(I)化合物相同。
在一些优选的实施方式中,本申请还涉及式(Ic)所示的化合物:
其中,X为-O-或-(NH)-;n、R3、R5、R6、Ra、Rb的定义以及优选项与式(I)化合物相同。
在一些优选的实施方式中,本申请还涉及式(IIa)所示的化合物:
其中,n、R5、R6、Ra、Rb的定义以及优选项与式(I)化合物相同。
在一些优选的实施方式中,本申请还涉及式(IIb)所示的化合物:
其中,n、R5、R6、Ra、Rb的定义以及优选项与式(I)化合物相同。
在一些更优选的实施方式中,本申请的化合物选自本申请各实施例所示的具体化合物。
本申请的化合物可以由本领域技术人员根据化合物具体结构由常规的有机合成方法合成得到。例如,式(I)化合物可以通过下述合成路线(I)或(II)所示的方法来制备。
合成路线(I)
例如,式(I)化合物可以通过上述合成路线(I)所示的方法来制备。中间体Int-2中的G选自卤素、羟基、甲磺酰基(OMs)、对甲苯磺酰基(OTs)等。PG1,PG2,和PG3为氨基保护基,例如四氢吡喃(THP)、苄基(Bn)、对甲氧基苄基(PMB)、SEM、Boc等。当G为卤素、OMs、或者OTs,中间体Int-1和Int-2在碱性条件下的SN2偶联反应可以生成中间体Int-3。当G为OH,中间体Int-3可以通过Int-1和Int-2之间的Mitsunobu反应来获得。中间体Int-3与中间体Int-4的缩合反应生成化合物Int-5。在氧化条件下(例如但不限于Swern氧化或者IBX氧化),Int-5转化为中间体Int-6。经过保护基的转换,中间体Int-6可以转换为Int-8。在典型的成酰胺反应条件下(例如但不限于在DIPEA/HATU的存在下),或者成磺酰胺的反应条件下,或者生成脲的反应条件下,或者SN2偶联反应条件下,或者生成氨基甲酸酯的反应条件下,Int-8与合适的起始原料反应,再将保护基脱除,可以得到目标化合物式(I)。
合成路线(II)
或者,化合物Int-7可以通过上述合成路线(II)所示的方法来制备。中间体Int-1与中间体Int-4的缩合反应生成化合物Int-9。在氧化条件下(例如但不限于Swern氧化或者IBX氧化),Int-9转化为中间体Int-10。经过保护基的转换,中间体Int-6可以转换为Int-11。PG1,PG2,和PG3为氨基保护基,例如但不限于四氢吡喃(THP)、苄基(Bn)、对甲氧基苄基(PMB)、SEM、Boc等。中间体Int-2中的G选自卤素、羟基、甲磺酰基(OMs)、对甲苯磺酰基(OTs)等。当G为卤素、OMs、或者OTs,中间体Int-11和Int-2在碱性条件下的SN2偶联反应可以生成中间体Int-7。当G为OH,中间体Int-7可以通过Int-11和Int-2之间的Mitsunobu反应来获得。
另外,本领域技术人员可以参照本申请具体实施例的具体化合物的合成路线,对反应原料和反应条件进行适当调整而得到其它化合物的合成方法。
本申请的化合物已被证明具有TRK激酶抑制活性,可以有效抑制TRKA、TRKB和/或TRKC,并且与拉罗替尼或恩曲替尼的抑制活性或选择性相当或更好,因此为广谱抗癌药物、止疼药和抗炎药等的开发提供了更多的选择和可能性。
在第二个方面,本申请提供了一种药物组合物,其含有如上文所述的本申请的化合物或其同位素标记化合物、或其光学异构体、几何异构体、互变异构体或异构体混合物、或其药学上可接受的盐、或其前药、或其代谢物,以及一种或多种药学上可接受的载体、佐剂或赋形剂。
本申请的药物组合物可以按制药领域中熟知的方式制备,并且可以通过多种途径施用,这取决于期望局部治疗还是全身性治疗并且取决于有待治疗的部位。给药可以是局部的(包括眼科的和至粘膜,包括鼻内、阴道和直肠递送)、肺部的(例如,通过吸入或吹入粉末或气溶胶,包括通过喷雾器;气管内、鼻内、表皮和经皮肤)、眼部的、经口的或肠胃外的。用于眼部递送的方法可以包括局部给药(滴眼剂),结膜下、眼周或玻璃体内注射或者通过用手术方法放置在结膜囊中的气囊式导管或眼科插入件引入。肠胃外给药包括静脉内、动脉内、皮下、腹膜内或肌内注射或输注;或颅内(例如,鞘内或脑室内)给药。肠胃外给药可以处于单次推注剂量的形式,或者可以例如通过连续灌注泵。用于局部给药的医药组合物和配制物可以包括透皮贴剂、软膏剂、洗剂、乳膏剂、凝胶剂、滴剂、栓剂、喷雾剂、液体以及粉剂。
如果使用固体载剂,则该制剂可以成片,以粉末或颗粒形式置于硬质凝胶胶囊中,或以糖锭或锭剂形式。固体载剂可以包括常规的赋形剂,诸如粘合剂、填料、成片润滑剂、崩解剂、润湿剂等等。如果需要可以通过常规技术膜包衣该片剂。如果使用液体载剂,则该制剂可以是糖浆、乳液、膏剂、软凝胶胶囊、用于注射的无菌载体、水性或非水性液体悬浮液形式的,或者可以是在使用前用水或其他适当载体复原的干品。液体制剂可以包含常规添加剂,诸如悬浮剂、乳化剂、润湿剂、非水性载体(包括可食用油)、防腐剂以及香味剂和/或着色剂。为了胃肠外施予,通常载体至少大部分包括无菌水,但也可以使用盐水溶液、葡萄糖溶液等。也可以使用可注射悬浮液,在这种情况下,可以使用常规悬浮剂。常规防腐剂、缓冲试剂等也可以添加到胃肠外剂型中。药物组合物通过对包含适量的活性成分(即本申请的化合物)的所需制剂合适的常规技术制备。
适于非肠道注射的组合物可以包括生理学上可接受无菌水性或非水性溶液、分散液、悬浮液或乳液和用于无菌可注射溶液或分散液的无菌粉末。合适的水性和非水性载体、稀释剂、溶剂的实例包括水、乙醇、多元醇(丙二醇、聚乙二醇、丙三醇等)、其合适的混合物、植物油(例如,橄榄油)和可注射有机酯(例如,油酸乙酯)。
这些组合物还可以包含各种赋形剂,例如,防腐剂、润湿剂、乳化剂和分散剂。可以通过各种抗菌剂和抗真菌剂(例如,对羟基苯甲酸酯、氯丁醇、苯酚、山梨酸等)来确保对微生物的作用的抑制。还可以包括等渗剂,例如,糖、氯化钠等。可以通过使用延迟吸收试剂(例如,单硬脂酸铝和凝胶)来延长可注射药学剂型的吸收。
用于口服的固体剂型包括胶囊、药片、药丸、粉末和颗粒。在这种固体剂型中,将活性化合物与至少一种惰性赋型剂(或载体)(例如,柠檬酸钠或磷酸二钙)混合,其中还可以包括:(a)填料或混合剂(例如,淀粉、乳糖、蔗糖、葡萄糖、甘露醇和硅酸);(b)粘结剂(例如,羧基甲基纤维素、褐藻酸酯、凝胶、聚乙烯基吡咯烷酮、蔗糖和阿拉伯树胶);(c)保湿剂(例如,丙三醇);(d)崩解剂(例如,琼脂-琼脂、碳酸钙、马铃薯或木薯淀粉、褐藻酸、某些合成的硅酸酯、碳酸钠);(e)溶液阻滞剂(例如,石蜡);(f)吸收促进剂(例如,季铵化合物);(I)润湿剂(例如,十六烷醇和单硬脂酸丙三醇酯);(h)吸附剂(例如,高岭土和斑脱土)和(i)润滑剂(例如,滑石、硬脂酸钙、硬脂酸镁、固体聚乙二醇、月桂基硫酸钠)或其混合物混合。
类似类型的固体组合物还可以在使用例如乳糖以及高分子量聚乙二醇等作为赋型剂的软填充和硬填充凝胶胶囊中作为填料。
固体剂型(例如,药片、糖衣丸、胶囊、药丸和颗粒)可以采用涂层和外壳(例如,肠道涂层和本领域已知的其它)来制备。它们可以包含遮光剂,它们还可以是以延迟方式在肠道的某一部分中释放活性化合物或各种活性化合物的组合物。可用的包埋组合物的实例是聚合物质和蜡。活性组分还可以以微胶囊化形式,如果适当的话,可以具有一种或更多种上述赋型剂。
用于口服的液体剂型包括药学上可接受乳液、溶液、分散液、糖浆和酏剂。除了活性化合物以外,液体剂型可以包含本领域中通常所用的惰性稀释剂(例如,水或其它溶剂)、增溶剂和乳化剂(例如,乙醇、异丙醇、碳酸乙酯、乙酸乙酯、苯甲醇、苯甲酸苯甲酯、丙二醇、1,3丁二醇、二甲基甲酰铵)、油(具体为,棉花子油、落花生油、玉米油、橄榄油、蓖麻油、芝麻油)、丙三醇、四氢呋喃醇、聚乙二醇和山梨聚糖的脂肪酸酯或这些物质的混合物等。
除了这些惰性稀释剂,组合物还可以包括,例如,润湿剂、乳化和悬浮剂、香化剂、调味剂和加香剂。
除了活性化合物,悬浮液可以包含悬浮剂,例如乙氧基化异十八烷醇、聚氧化乙烯山梨醇、山梨聚糖酯、微晶纤维、偏氢氧化铝、斑脱土、琼脂-琼脂和黄芪胶或这些物质的混合物等。
本申请的化合物的局部给药用剂型包括膏剂、粉末、喷雾和吸入剂。该活性组分在无菌条件下与生理学上可接受载体和任何所需要的防腐剂、缓冲剂或推进剂混合。眼用配方、眼药膏、粉末和溶液也包括在本申请的范围内。
本申请的化合物在药物组合物和剂型中的量可以由本领域技术人员根据需要适当地确定,例如本申请的化合物可以治疗有效量存在于药物组合物或剂型中。
在第三个方面,本申请提供了本申请的化合物或其同位素标记化合物、或其光学异构体、几何异构体、互变异构体或异构体混合物、或其药学上可接受的盐、或其前药、或其代谢物,或如上文所述的药物组合物在制备用于治疗与TRK激酶或NTRK基因相关的疾病或病症的药物中的用途。
本申请也提供了治疗与TRK激酶或NTRK基因相关的疾病或病症的方法,所述方法包括向有此需要的患者施用治疗有效量的本申请的化合物或其同位素标记化合物、或其光学异构体、几何异构体、互变异构体或异构体混合物、或其药学上可接受的盐、或其前药、或其代谢物,或如上文所述的药物组合物。其中,所述患者优选是哺乳动物,更优选是人类患者。其中给药途径可以是口服、外用(包括但不限于外敷、喷涂等)、胃肠外(包括皮下、肌肉、皮层和静脉)施予、支气管施予或鼻施予等。
所述与TRK激酶或NTRK基因相关的疾病或病症,例如是由TRK激酶活性失调引起的和/或与NTRK基因融合相关疾病,例如但不限于:癌症、疼痛、炎症、神经变性疾病和细胞增殖疾病。本申请的化合物可例如用于抑制癌细胞的增殖、转移等,用于缓解疼痛,用于消炎,用于治疗或缓解神经变性疾病等等。
在一些实施方式中,所述与TRK激酶或NTRK基因相关的疾病或病症是癌症。
示例性癌症包括膀胱癌、乳腺癌、子宫颈癌、结肠直肠癌、小肠癌、结肠癌、直肠癌、肛门癌、子宫内膜癌、头颈癌(例如,喉、喉咽、鼻咽、口咽、唇部和口腔的癌症)、肾癌、肝癌(例如,肝细胞癌、胆管细胞癌)、肺癌(例如,腺癌、小细胞肺癌和非小细胞肺癌、小细胞癌和非小细胞癌、支气管癌、支气管腺瘤、胸膜肺母细胞瘤)、卵巢癌、前列腺癌、睾丸癌、子宫癌、食管癌、胆囊癌、胰腺癌(例如外分泌胰腺癌)、甲状腺癌、副甲状腺癌、皮肤癌(例如,鳞状细胞癌、卡波西肉瘤、梅克尔(Merkel)细胞皮肤癌)以及脑癌(例如,星状细胞瘤、神经管胚细胞瘤、室管膜瘤、神经外胚层肿瘤、松果体肿瘤)。
另外的示例性癌症包括造血系统恶性肿瘤,如白血病或淋巴瘤、多发性骨髓瘤、慢性淋巴细胞性淋巴瘤、成人T细胞白血病、B细胞淋巴瘤、皮肤T细胞淋巴瘤、急性骨髓性白血病、霍奇金或非霍奇金淋巴瘤、骨髓增生性肿瘤(例如,真性红细胞增多症、原发性血小板增多症和原发性骨髓纤维化)、瓦登斯特隆巨球蛋白血症、毛细胞淋巴瘤、慢性骨髓性淋巴瘤、急性淋巴母细胞性淋巴瘤、AIDS相关的淋巴瘤以及柏基特淋巴瘤。
另外的示例性癌症包括眼睛肿瘤、神经胶母细胞瘤、黑色素瘤、横纹肌肉瘤、淋巴肉瘤以及骨肉瘤。
在一些优选的实施方式中,所述与TRK激酶或NTRK基因相关的疾病或病症选自肝细胞癌、乳腺癌、膀胱癌、结肠直肠癌、黑色素瘤、间皮瘤、肺癌、前列腺癌、膜腺癌、胰腺癌、食道癌、胃癌、淋巴癌、白血病、鼻咽癌、睾丸癌、甲状腺癌、鳞状细胞癌、神经胶母细胞瘤、成神经细胞瘤、子宫癌以及横纹肌肉瘤。
在一些优选的实施方式中,所述与TRK激酶或NTRK基因相关的疾病或病症为实体瘤,如黑素瘤、乳腺瘤、以及神经母细胞瘤、胶质母细胞瘤、尤因肉瘤、视网膜母细胞瘤等。
在另一些实施方式中,所述与TRK激酶或NTRK基因相关的疾病或病症是细胞增殖疾病,例如,但不限于良性前列腺增生,家族性腺瘤病,息肉病,神经纤维瘤病,银屑病,动脉粥样硬化和与血管平滑细胞增殖和新生内膜形成有关的疾病,例如血管成形术或手术后的再狭窄、肺纤维化、关节炎、肾小球肾炎,视网膜病变(包括糖尿病性和新生儿视网膜病变和老年性黄斑变性),移植血管疾病(例如可能在血管或器官移植后发生),肢端肥大症和肢端肥大症继发性病症等。
在另一些实施方式中,所述与TRK激酶或NTRK基因相关的疾病或病症是炎症,包括但不限于:(1)变质性炎症;(2)渗出性炎症(浆液性炎、纤维素性炎、化脓性炎、出血性炎、坏死性炎、卡他性炎);(3)增生性炎症;(4)特异性炎症(结核、梅毒、麻疯、淋巴肉芽肿等)。
在另一些实施方式中,所述与TRK激酶或NTRK基因相关的疾病或病症是疼痛,包括但不限于炎性疼痛、关节炎疼痛、复杂区域性疼痛综合征、腰尻痛、肌肉骨骼痛、神经性疼痛、慢性疼痛、癌症相关疼痛、急性疼痛、术后疼痛等。
在另一些实施方式中,所述与TRK激酶或NTRK基因相关的疾病或病症是神经变性疾病,包括但不限于阿尔茨海默病和帕金森病。
用于治疗上述疾病的本申请化合物的“治疗有效量”可有有经验的医师或研究人员根据患者的病情、身体状况、疾病严重程度、给药途径等因素予以合理地确定。
下面结合具体实施例对本申请做进一步的说明和描述。
实施例
以下在本文中阐述的实施例仅仅为了说明目的,用以举例说明本发明的各个方面以及实施方式,并不意欲以任何方式限制本发明所要求保护的范围。
除非另有声明,所有原料和试剂均从商业途径获得。合成实验和产物分析检测中所用仪器设备等均为有机合成中通常使用的常规仪器和设备。所有未特别注明的反应条件和测试条件均为本领域中通常使用的常规反应条件和测试条件,可通过参考相关技术文献或仪器说明书等获得。
实施例1:N-(1-(1-(3,5-二氟苯基)乙基)-3-(1,4,5,6-四氢吡咯并[3,4-d]咪唑-
2-基)-1H-吲唑-5-胺
化合物1的合成路线:
中间体1-8的合成路线
合成方法:
合成中间体1-1:5-硝基-1H-吲唑-3-甲醛
亚硝酸钠(1.7g,24.70mmol)溶于9ml DMF和5ml水中,冷却到0℃,缓慢滴加3N HCl(7.2ml,21.61mmol),滴加完反应10分钟。在0℃下,向反应液中加入5-硝基-1H-吲哚(501mg,3.10mmol)的DMF(6ml)溶液,滴加完,加热到80℃反应过夜。用乙酸乙酯萃取3次,合并有机相,用水洗3次,饱和食盐水洗,无水硫酸钠干燥,浓缩,硅胶柱纯化,得370mg中间体1-1,收率62.6%。
1H NMR(400MHz,DMSO)δ14.71(brs,1H),10.26(s,1H),8.95(d,J=8.0Hz,1H),8.33(dd,J=8.0Hz,J=12.0Hz,1H),7.93(d,J=16.0Hz,1H).
合成中间体1-2:5-硝基-1-(四氢-2H-吡喃-2-基)-1H-吲唑-3-甲醛
将中间体1-1(370mg,1.94mmol)溶于30ml DCM中,加入对甲苯磺酸(333mg,1.94mmol),搅拌2分钟,向反应液中加入3,4-二氢-2H-吡喃(326mg,3.87mmol),室温反应2小时。向反应液中加水,用DCM萃取2次,合并有机相,分别用饱和碳酸氢钠溶液和饱和食盐水洗涤,无水硫酸钠干燥,浓缩,硅胶柱纯化,得380mg中间体1-2,收率71.3%。
1H NMR(400MHz,CDCl3)δ10.30(s,1H),9.26(d,J=4.0Hz,1H),8.39-8.36(m,1H),7.82(d,J=8.0Hz,1H),5.93-5.90(m,1H),4.04-3.99(m,1H),3.86-3.80(m,1H),2.60-2.52(m,1H),2.23-2.20(m,2H),1.84-1.78(m,3H).
合成中间体1-9:2,5-二氢-1H-吡咯-1甲酸叔丁酯
将3-吡咯啉(10.0g,0.15mol)溶于400ml二氯甲烷和三乙胺(40.6ml,0.29mol)中,冷却到0度,缓慢加入(Boc)2O(37.9g,0.17mol),室温反应过夜,加入水,用二氯甲烷萃取2次,合并有机相,用水洗3次,饱和食盐水洗,无水硫酸钠干燥,浓缩,硅胶柱纯化,得中间体1-9,收率91.0%。
合成中间体1-10:6-氧杂-3-氮杂双环并[3.1.0]己烷-3-甲酸叔丁酯
将中间体1-9(24.5g,0.15mol)溶于450ml二氯甲烷中,冷却到0度,分批缓慢加入间氯过氧苯甲酸(37.5g,0.22mol),室温反应过夜,加入饱和硫代硫酸钠(40ml),搅拌30分钟,水相用二氯甲烷萃取2次,用饱和碳酸钾溶液,水和饱和食盐水洗,无水硫酸钠干燥,浓缩,硅胶柱纯化,得中间体1-10,收率84.9%。
1H NMR(400MHz,CDCl3)δ3.85(d,J=12.0Hz,1H),3.77(d,J=12.0Hz,1H),3.69-3.67(m,2H),3.36-3.30(m,2H),1.45(s,9H).
合成中间体1-11:3-叠氮基-4-羟基吡咯烷基-1-甲酸叔丁酯
将中间体1-10(20.8g,0.12mol)溶于150ml 1,4-二氧六环和50ml水中,加入叠氮化钠(24.0g,0.37mol),加热到106度反应18小时,冷却到室温,加入饱和食盐水100ml,用二氯甲烷萃取(250ml x 4),合并有机相,用饱和食盐水洗,无水硫酸钠干燥,浓缩,得中间体1-11,收率100%。1HNMR(400MHz,CDCl3)δ4.27-4.24(m,1H),3.94(s,1H),3.73-3.59(m,2H),3.41-3.36(m,2H),1.47(s,9H).
合成中间体1-12:3-叠氮基-4-((甲磺酰基)氧基)吡咯烷基-1-甲酸叔丁酯
将中间体1-11(28.0g,0.12mol)溶于350ml二氯甲烷和三乙胺(37.3g,0.37mol)中,冷却到0度,缓慢滴加甲磺酰氯(16.9g,0.15mol),滴加完后,室温反应2小时,加入水淬灭反应,用二氯甲烷萃取2次,合并有机相,用饱和碳酸氢钠溶液,水和饱和食盐水洗,无水硫酸钠干燥,浓缩,得中间体1-12,收率98.0%。
合成中间体1-13:3,4-二叠氮基吡咯烷基-1-甲酸叔丁酯
将中间体1-12(36.9g,0.12mol)溶于250ml DMF中,加入叠氮化钠(23.5g,0.36mol),加热到90度,反应2天,冷却到室温,加入750ml水,用甲基叔丁基醚萃取(400ml*4),合并有机相,用饱和食盐水洗,无水硫酸钠干燥,硅胶柱纯化,得中间体1-13,收率62.2%。
合成中间体1-8:3,4-二氨基吡咯烷基-1-甲酸叔丁酯
将中间体1-13(18.9g,0.08mol)溶于200ml甲醇中,加入10%Pd/C,氢气置换3次,加热到40度,反应2天,过滤,浓缩,得中间体1-8,收率78%。1H NMR(400MHz,CDCl3)δ3.51-3.49(m,2H),3.40-3.36(m,2H),3.21-3.11(m,2H),1.47(s,9H).
合成中间体1-3:2-(5-硝基-1-(四氢-2H-吡喃-2-基)-1H-吲唑-3-基)-3a,4,6,6a-四氢吡咯并[3,4-d]咪唑-5(1H)-羧酸叔丁酯
将中间体1-2(300mg,1.09mmol)溶于20ml叔丁醇中,加入3,4-二氨基吡咯烷-1-羧酸叔丁酯(219mg,1.09mmol),碘(415mg,1.63mmol),碳酸钾(452mg,3.27mmol),升温70℃反应3小时。反应完成后,降至室温,加5%的硫代硫酸钠水溶液淬灭反应,加EA萃取,有机相用饱和食盐水洗涤,无水硫酸钠干燥,浓缩,硅胶柱纯化,得410mg中间体1-3,收率82.4%。
合成中间体1-4:2-(5-硝基-1-(四氢-2H-吡喃-2-基)-1H-吲唑-3-基)-4,6-二氢吡咯并[3,4-d]咪唑-5(1H)-羧酸叔丁酯
将中间体1-3(400mg,0.88mmol)溶于5ml DMSO中,加入IBX(491mg,1.75mmol),升温50℃反应3小时。反应完成后,降至室温,加水淬灭反应,加EA萃取,有机相用饱和食盐水洗涤,无水硫酸钠干燥,浓缩,硅胶柱纯化,得270mg中间体1-4,收率67.8%。
合成中间体1-5:2-(5-硝基-1-(四氢-2H-吡喃-2-基)-1H-吲唑-3-基)-1-((2-(三甲基甲硅烷基)乙氧基)甲基)-4,6-二氢吡咯并[3,4-d]咪唑-5(1H)-羧酸叔丁酯
将中间体1-4(270mg,0.59mmol)溶于25ml THF中,降温至0℃,加入NaH(60%)(35.6mg,0.89mmol),搅拌10mim,加入SEMCl(149mg,0.89mmol)。加入完毕后升至室温搅拌,反应完成后,加水淬灭,加EA萃取,有机相用饱和食盐水洗涤,无水硫酸钠干燥,浓缩,硅胶柱纯化,得209mg中间体1-5,收率60.2%。
1H NMR(400MHz,CDCl3)δ9.51(d,J=8.0Hz,1H),8.33(d,J=8.0Hz,1H),7.69(d,J=8.0Hz,1H),5.99-5.94(m,1H),5.90-5.87(m,1H),5.81-5.79(m,1H),4.63-4.52(m,4H),4.00-3.98(m,1H),3.79-3.77(m,1H),3.62-3.56(m,2H),2.55-2.52(m,1H),2.20-2.17(m,2H),1.79-1.76(m,3H),1.54(s,9H),0.95-0.89(m,2H),-0.08(s,9H).
合成中间体1-6:2-(5-胺基-1-(四氢-2H-吡喃-2-基)-1H-吲唑-3-基)-1-((2-(三甲基甲硅烷基)乙氧基)甲基)-4,6-二氢吡咯并[3,4-d]咪唑-5(1H)-羧酸叔丁酯
将中间体1-5(200mg,0.34mmol)溶于60ml甲醇中,加入10%Pd/C(20mg),氢气置换3次,室温反应3小时。反应完成后,过滤,浓缩,得173mg中间体1-6,收率91.2%。
合成中间体1-7:2-(5-((1-(3,5-二氟苯基)乙基)胺基)-1-(四氢-2H-吡喃-2-基)-1H-吲唑-3-基)-1-((2-(三甲基甲硅烷基)乙氧基)甲基)-4,6-二氢吡咯并[3,4-d]咪唑-5(1H)-羧酸叔丁酯
将中间体1-6(20.0mg,0.04mmol)和3,5-二氟苯乙酮(6.8mg,0.04mmol)溶于5ml甲苯中,加入1滴冰醋酸,加热至80℃反应过夜,冷却到室温向反应液中加入三乙酰基硼氢化钠(9.9mg,0.05mmol),室温反应3小时,加水淬灭,用EA萃取,用饱和食盐水洗涤,浓缩纯化得9mg中间体1-7,收率35.9%。
合成化合物1:N-(1-(1-(3,5-二氟苯基)乙基)-3-(1,4,5,6-四氢吡咯并[3,4-d]咪唑-2-基)-1H-吲唑-5-胺
将中间体1-7(10.0mg,0.05mmol)溶于2ml甲醇中,加入1ml浓盐酸,50℃反应5小时,浓缩,溶于5ml甲醇,加0.5ml氨水,浓缩,制备板纯化,得到最终产物2.1mg,收率38.3%。
1H NMR(400MHz,CD3OD)δ7.33(d,J=8.0Hz,1H),7.18(d,J=4.0Hz,1H),7.10-7.06(m,2H),6.98(dd,J=4.0Hz,J=8.0Hz,1H),6.74-6.69(m,1H),4.70-4.65(m,1H),4.18(s,4H),1.55(d,J=8.0Hz,3H).
实施例2:N-(3,5-二氟苄基)-3-(5-(哌啶-4-基甲基)-1,4,5,6-四氢吡咯并[3,4-
d]咪唑-2-基)-1H-吲唑-5-胺
化合物2的合成路线:
合成方法:
合成中间体2-1:2-(5-((3,5-二氟苄基)胺基)-1-(四氢-2H-吡喃-2-基)-1H-吲唑-3-基)-1-((2-(三甲基甲硅烷基)乙氧基)甲基)-4,6-二氢吡咯并[3,4-d]咪唑-5(1H)-羧酸叔丁酯
将中间体1-6(80.0mg,0.14mmol)和3,5-二氟苯甲醛(24.6mg,0.17mmol)溶于5ml甲苯中,加入1滴冰醋酸,加热至80℃反应过夜,冷却到室温向反应液中加入三乙酰基硼氢化钠(45.9mg,0.22mmol),室温反应3小时,加水淬灭,用EA萃取,用饱和食盐水洗涤,浓缩纯化得79mg中间体2-1,收率80.5%。
合成中间体2-2:N-(3,5-二氟苄基)-1-(四氢-2H-吡喃-2-基)-3-(1-((2-(三甲基甲硅烷基)乙氧基)甲基)-1,4,5,6-四氢吡咯并[3,4-d]咪唑-2-基)-1H-吲唑-5-胺
将中间体2-1(79.0mg,0.12mmol)溶于20ml DCM中,加入ZnBr2(105.0mg,0.46mmol),室温下搅拌。反应完成后,加水淬灭,加DCM萃取,有机相用饱和食盐水洗涤,无水硫酸钠干燥,浓缩,得60.2mg中间体2-2,收率89.4%。
合成中间体2-3:4-((2-(5-((3,5-二氟苄基)氨基)-1-(四氢-2H-吡喃-2-基)-1H-吲唑-3-基)-1-((2-(三甲基甲硅烷基)乙氧基)甲基)-4,6-二氢吡咯并[3,4-d]咪唑-5(1H)-基)甲基)哌啶-1-羧酸叔丁酯
将中间体2-2(67.5mg,0.12mmol)和4-甲酰基哌啶-1-羧酸叔丁酯(29.7mg,0.14mmol)溶于10ml DCM中,室温搅拌10分钟,加入三乙酰基硼氢化钠(37.0mg,0.17mmol),室温反应3小时,加水淬灭,用DCM萃取,用饱和食盐水洗涤,浓缩纯化得24.9mg中间体2-3,收率27.5%。
合成化合物2:N-(3,5-二氟苄基)-3-(5-(哌啶-4-基甲基)-1,4,5,6-四氢吡咯并[3,4-d]咪唑-2-基)-1H-吲唑-5-胺
将中间体2-3(24.9mg,0.03mmol)溶于2ml甲醇中,加入1ml浓盐酸,50℃反应5小时,浓缩,溶于5ml甲醇,加0.5ml氨水,浓缩,制备板纯化,得到最终产物5.1mg,收率34.4%。
1H NMR(400MHz,CD3OD)δ7.37(d,J=8.0Hz,1H),7.30(d,J=4.0Hz,1H),7.08(dd,J=4.0Hz,J=16.0Hz,2H),7.01(dd,J=4.0Hz,J=8.0Hz,1H),6.80-6.75(m,1H),4.46(s,2H),3.90(s,4H),3.19-3.15(m,2H),2.78-2.72(m,4H),2.06-2.04(m,1H),1.96-1.91(m,2H),1.81-1.78(m,1H),1.62-1.57(m,1H).
实施例3:5-(3,5-二氟苄基)-3-(5-(甲基磺酰基)-1,4,5,6-四氢吡咯并[3,4-d]
咪唑-2-基)-1H-吲唑
化合物3的合成路线:
合成方法:
合成中间体3-1:5-溴-1H-吲唑-3-甲醛
将亚硝酸钠(1.41g,20.4mmol)溶于10ml水中,加入10ml DMF,0℃滴加3M HCl(2.29ml,6.89mmol),搅拌10分钟,向反应液中加入5-溴吲哚(500mg,2.55mmol)的DMF(10ml)溶液,室温反应3小时。向反应液中加水,用乙酸乙酯萃取2次,合并有机相,用饱和食盐水洗涤,无水硫酸钠干燥,浓缩,硅胶柱纯化,得中间体3-1 410mg,收率71.4%。
1H NMR(400MHz,CDCl3)δ10.28(s,1H),8.53(d,J=1.1Hz,1H),7.61(dd,J=8.9,1.8Hz,1H),7.49(d,J=8.8,1H).
合成中间体3-2:5-溴-1-(四氢-2H-吡喃-2-基)-1H-吲唑-3-甲醛
将中间体3-1(300mg,1.33mmol)溶于20ml DCM中,加入对甲苯磺酸(279mg,1.46mmol),搅拌2分钟,向反应液中加入3,4-二氢-2H-吡喃(168mg,2.0mmol)的DCM(3ml)溶液,室温反应1小时。向反应液中加水,用DCM萃取2次,合并有机相,分别用饱和碳酸氢钠溶液和饱和食盐水洗涤,无水硫酸钠干燥,浓缩,硅胶柱纯化,得中间体3-2 300mg,收率72.8%。
合成中间体3-3:5-溴-3-(二甲氧基甲基)-1-(四氢-2H-吡喃-2-基)-1H-吲唑
将中间体3-2(50.0mg,0.16mmol),原甲酸三甲酯(20.6mg,0.19mmol)和对甲苯磺酸(2.8mg,0.02mmol)溶于5ml甲醇中,室温反应2小时,加水淬灭,用EA萃取,用饱和食盐水洗涤,无水硫酸钠干燥,浓缩纯化得23mg中间体3-3,收率40.0%。
1H NMR(400MHz,CDCl3)δ8.13(d,J=4.0Hz,1H),7.52-7.46(m,2H),5.74(s,1H),5.72-5.69(m,1H),4.08-4.04(m,1H),3.78-3.72(m,1H),3.47(s,6H),2.52-2.48(m,1H),2.15-2.04(m,2H),1.80-1.71(m,3H).
合成中间体3-4:3-(二甲氧基甲基)-1-(四氢-2H-吡喃-2-基)-5-(4,4,5,5-四甲基-1,3,2-二氧杂硼烷-2-基)-1H-吲唑
将中间体3-3(20.0mg,0.06mmol),频哪醇硼酸酯(28.6mg,0.11mmol),Pd(dppf)Cl2(4.1mg,0.006mmol)和醋酸钾(16.6mg,0.17mmol)溶于10ml1,4-二氧六环中,氮气置换3次,加热到100℃反应过夜,加水淬灭,加EA萃取,有机相用饱和食盐水洗涤,无水硫酸钠干燥,浓缩薄层析,得15mg中间体3-4,收率66.2%。
1H NMR(400MHz,CDCl3)δ8.45(s,1H),7.82(dd,J=4.0Hz,J=8.0Hz,1H),7.58(dd,J=8.0,4.0Hz,1H),5.81(s,1H),5.76(dd,J=8.0,4.0Hz,1H),4.11-4.07(m,1H),3.78-3.75(m,1H),3.48(s,6H),2.60-2.51(m,1H),2.16-2.03(m,2H),1.79-1.60(m,3H),1.38(s,12H).
合成中间体3-5:5-(3,5-二氟苄基)-3-(二甲氧基甲基)-1-(四氢-2H-吡喃-2-基)-1H-吲唑
将中间体3-4(175mg,0.44mmol),3,5-二氟溴苄(180mg,0.87mmol),Pd(PPh3)4(50.2mg,0.04mmol)和碳酸钠(138mg,1.31mmol)溶于10ml四氢呋喃和2ml的水中,氮气置换3次,加热到65℃反应过夜,加水淬灭,加EA萃取,有机相用饱和食盐水洗涤,无水硫酸钠干燥,浓缩柱层析,得148mg中间体3-5,收率84.5%。
合成中间体3-6:5-(3,5-二氟苄基)-1-(四氢-2H-吡喃-2-基)-1H-吲唑-3-甲醛
将中间体3-5(50mg,0.12mmol),对甲苯磺酸(47.3mg,0.25mmol)溶于10ml乙腈中,室温反应。反应完成后加水淬灭,加EA萃取,有机相用饱和食盐水洗涤,无水硫酸钠干燥,浓缩柱层析,得27mg中间体3-6,收率61.0%。
1H NMR(400MHz,CDCl3)δ10.27(s,1H),8.18(s,1H),7.64(d,J=8.4Hz,1H),7.31-7.28(m,1H),6.74-6.63(m,3H),5.84(dd,J=8.9,2.9Hz,1H),4.11(s,2H),4.06-3.99(m,1H),3.83-3.77(m,1H),2.63-2.55(m,1H),2.26-2.14(m,2H),1.85-1.74(m,3H).
合成中间体3-7:2-(5-(3,5-二氟苄基)-1-(四氢-2H-吡喃-2-基)-1H-吲唑-3-基)-3a,4,6,6a-四氢吡咯并[3,4-d]咪唑-5(1H)-羧酸叔丁酯
将中间体3-6(50mg,0.14mmol)溶于10ml叔丁醇中,加入3,4-二氨基吡咯烷-1-羧酸叔丁酯(28.2mg,0.14mmol),碘(53.4mg,0.21mmol),碳酸钾(58.2mg,0.42mmol),升温70℃反应3小时。反应完成后,降至室温,加5%的硫代硫酸钠水溶液淬灭反应,加EA萃取,有机相用饱和食盐水洗涤,无水硫酸钠干燥,浓缩,硅胶柱纯化,得中间体3-7 68mg,收率90.2%。
合成中间体3-8:2-(5-(3,5-二氟苄基)-1-(四氢-2H-吡喃-2-基)-1H-吲唑-3-基)-4,6-二氢吡咯并[3,4-d]咪唑-5(1H)-羧酸叔丁酯
将中间体3-7(65mg,0.12mmol)溶于10ml DMSO中,加入IBX(67.7mg,0.24mmol),升温50℃反应3小时。反应完成后,降至室温,加水淬灭反应,加EA萃取,有机相用饱和食盐水洗涤,无水硫酸钠干燥,浓缩,硅胶柱纯化,得中间体3-8 34mg,收率52.5%。
1H NMR(400MHz,CDCl3)δ8.33(s,1H),7.53(d,J=8.8Hz,1H),7.24(dd,J=8.8,1.7Hz,1H),6.74-6.71(m,1H),6.67-6.60(m,2H),5.72(dd,J=9.6,2.6Hz,1H),4.60-4.54(m,4H),4.13(s,2H),4.10-4.06(m,1H),3.81-3.75(m,1H),2.62-2.54(m,1H),2.16-2.06(m,2H),1.85-1.70(m,3H),1.55(s,9H).
合成中间体3-9:2-(5-(3,5-二氟苄基)-1-(四氢-2H-吡喃-2-基)-1H-吲唑-3-基)-1-((2-(三甲基甲硅烷基)乙氧基)甲基)-4,6-二氢吡咯并[3,4-d]咪唑-5(1H)-羧酸叔丁酯
将中间体3-8(19.8mg,0.04mmol)溶于5ml THF中,降温至0℃,加入NaH(60%)(1.9mg,0.05mmol),搅拌15mim,加入SEMCl(6.7mg,0.04mmol)。加入完毕后升至室温搅拌,反应完成后,加水淬灭,加EA萃取,有机相用饱和食盐水洗涤,无水硫酸钠干燥,浓缩,硅胶柱纯化,得中间体3-9 18.1mg,收率73.4%。
合成中间体3-10:5-(3,5-二氟苄基)-1-(四氢-2H-吡喃-2-基)-3-(1-((2-(三甲基甲硅烷基)乙氧基)甲基)-1,4,5,6-四氢吡咯[3,4-d]咪唑-2-基)-1H-吲唑
将中间体3-9(182mg,0.27mmol)溶于20ml DCM中,加入ZnBr2(24mg,1.10mmol),室温下搅拌。反应完成后,加水淬灭,加DCM萃取,有机相用饱和食盐水洗涤,无水硫酸钠干燥,浓缩,得中间体3-10 140mg,收率90.3%。
合成化合物3:5-(3,5-二氟苄基)-3-(5-(甲基磺酰基)-1,4,5,6-四氢吡咯并[3,4-d]咪唑-2-基)-1H-吲唑
将中间体3-10(30.0mg,0.05mmol)5ml DCM中,向溶液中加入TEA(8.0mg,0.08mmol),甲磺酰氯(7.3mg,0.06mmol)。反应完成后,加水淬灭,用DCM萃取,合并有机相,用饱和食盐水洗涤,浓缩。将浓缩物溶于4ml甲醇中,加入2ml浓盐酸,50℃反应3小时,浓缩,溶于5ml甲醇,加0.5ml氨水,浓缩,制备板纯化,得到最终产物5.6mg,收率24.6%。
1H NMR(400MHz,CD3OD)δ8.18(s,1H),7.53(d,J=8.4Hz,1H),7.32(dd,J=8.7,4.0Hz,1H),6.91-6.85(m,2H),6.78-6.73(m,1H),4.66-4.52(m,4H),3.65(s,2H),3.01(s,3H).
实施例4:5-(1-(3,5-二氟苯基)乙氧基)-3-(5-(1-甲基哌啶-4-基)-1,4,5,6-四
氢吡咯并[3,4-d]咪唑-2-基)-1H-吲唑
化合物4的合成路线:
合成方法:
合成中间体4-1:1-(3,5-二氟苯基)乙醇
将3,5-二氟苯乙酮(2.1g,13.50mmol)溶于20ml甲醇中,0℃分批加入氰基硼氢化钠(1.3g,20.21mmol),加完转移至室温搅拌1小时,反应完毕。向反应液中加水,用乙酸乙酯萃取2次,合并有机相,用饱和食盐水洗涤,无水硫酸钠干燥,浓缩得粗品中间体4-1 2.13g,收率100.1%。
合成中间体4-2:1-(3,5-二氟苯基)甲磺酸乙酯
将中间体4-1(2.13g,13.50mmol)溶于20ml二氯甲烷中,加入三乙胺(4.1g,40.41mmol),0℃滴加甲磺酰氯(1.9g,16.20mmol),加完转移至室温搅拌1小时,反应完毕。向反应液中加水,用乙酸乙酯萃取2次,合并有机相,用饱和食盐水洗涤,无水硫酸钠干燥,浓缩,硅胶柱纯化,得粗品中间体4-2 3.2g,收率100%。
合成中间体4-3:5-(1-(3,5-二氟苯基)乙氧基)-1-(四氢-2H-吡喃-2-基)-1H-吲唑-3-甲醛
将中间体4-2(2.2g,9.30mmol)和5-羟基-1-(四氢-2H-吡喃-2-基)-1H-吲唑-3-甲醛(2.3g,18.61mmol)溶于20ml DMF中,加入碳酸铯(6.1g,0.82mmol),60℃反应2小时,反应完毕。向反应液中加水,用乙酸乙酯萃取2次,合并有机相,用饱和食盐水洗涤,无水硫酸钠干燥,浓缩,硅胶柱纯化,得中间体4-3 3.1g,收率86.2%。
1H NMR(400MHz,CDCl3)δ10.19(s,1H),7.72-7.45(m,2H),7.19-7.16(m,1H),7.00-6.92(m,2H),6.73-6.67(m,1H),5.81-5.77(m,1H),5.43(q,J=6.3Hz,1H),4.03-3.98(m,1H),3.81-3.75(m,1H),2.56-2.49(m,1H),2.26-2.03(m,2H),1.82-1.71(m,3H),1.67(d,J=6.3Hz,3H).
合成中间体4-4:2-(5-(1-(3,5-二氟苯基)乙氧基)-1-(四氢-2H-吡喃-2-基)-1H-吲唑-3-基)-3a,4,6,6a-四氢吡咯并[3,4-d]咪唑-5(1H)-羧酸叔丁酯
将中间体4-3(3.1g,8.01mmol)溶于30ml叔丁醇中,加入3,4-二氨基吡咯烷-1-羧酸叔丁酯(1.6g,8.01mmol),碘(3.1g,12.11mmol),碳酸钾(3.3g,24.02mmol),升温70℃反应3小时。反应完成后,降至室温,加5%的硫代硫酸钠水溶液淬灭反应,加EA萃取,有机相用饱和食盐水洗涤,无水硫酸钠干燥,浓缩,硅胶柱纯化,得中间体4-4 3.6g,收率79.1%。
1H NMR(400MHz,CDCl3)δ7.74(s,1H),7.49(dd,J=9.1Hz,3.2Hz,1H),7.11(dd,J=9.1Hz,2.4Hz,1H),7.00(d,J=7.3Hz,2H),6.69(t,J=9.0Hz,1H),5.70-5.67(m,1H),5.49-5.44(m,1H),5.00-4.80(m,1H),4.52-4.31(m,1H),4.03-3.99(m,1H),3.77-3.66(m,5H),2.56-2.47(m,1H),2.18-2.10(m,1H),2.06-2.02(m,1H),1.79-1.72(m,3H),1.66-1.64(m,3H),1.45(s,9H).
合成中间体4-5:2-(5-(1-(3,5-二氟苯基)乙氧基)-1-(四氢-2H-吡喃-2-基)-1H-吲唑-3-基)-4,6-二氢吡咯[3,4-d]咪唑-5(1H)-羧酸叔丁酯
将中间体4-4(1.3g,2.31mmol)溶于10ml DMSO中,加入IBX(1.3g,4.60mmol),升温50℃反应3小时。反应完成后,降至室温,加水淬灭反应,加EA萃取,有机相用饱和食盐水洗涤,无水硫酸钠干燥,浓缩,硅胶柱纯化,得中间体4-5 560mg,收率43.2%。
合成中间体4-6:2-(5-(1-(3,5-二氟苯基)乙氧基)-1-(四氢-2H-吡喃-2-基)-1H-吲唑-3-基)-1-((2-(三甲基甲硅烷基)乙氧基)甲基)-4,6-二氢吡咯并[3,4-d]咪唑-5(1H)-羧酸叔丁酯
将中间体4-5(790mg,1.40mmol)溶于10ml THF中,降温至0℃,加入NaH(60%)(96.4mg,4.20mmol),搅拌15mim,加入SEMCl(280mg,1.68mmol)。加入完毕后升至室温搅拌,反应完成后,加水淬灭,加EA萃取,有机相用饱和食盐水洗涤,无水硫酸钠干燥,浓缩,硅胶柱纯化,得中间体4-6 810mg,收率83.3%。
合成中间体4-7:5-(1-(3,5-二氟苯基)乙氧基)-1-(四氢-2H-吡喃-2-基)-3-(1-((2-(三甲基甲硅烷基)乙氧基)甲基)-1,4,5,6-四氢吡咯并[3,4-d]咪唑-2-基)-1H-吲唑
将中间体4-6(810.0mg,1.20mmol)溶于20ml DCM中,加入ZnBr2(1.1g,4.70mmol),室温下搅拌。反应完成后,加水淬灭,加DCM萃取,有机相用饱和食盐水洗涤,无水硫酸钠干燥,浓缩,得中间体4-7 660mg,收率95.2%。
合成化合物4:5-(1-(3,5-二氟苯基)乙氧基)3-(5-(1-甲基哌啶-4-基)-1,4,5,6-四氢吡咯并[3,4-d]咪唑-2-基)-1H-吲唑
将中间体4-7(15.0mg,0.03mmol)和1-甲基哌啶-4-酮(4.3mg,0.04mmol),溶于5mlDCM中,室温搅拌10分钟,加入三乙酰氧基硼氢化钠(8.01mg,0.04mmol),室温搅拌3小时。反应完成后,加水淬灭,用DCM萃取,用饱和食盐水洗涤,浓缩。硅胶板纯化,将纯化所得产物溶于2ml甲醇中,加入1ml浓盐酸,50℃反应5小时,浓缩,溶于5ml甲醇,加0.5ml氨水,浓缩,制备板纯化,得到最终产物1.9mg,两步总收率15.8%。
1H NMR(400MHz,CD3OD)δ7.67(d,J=4.0Hz,1H),7.50(d,J=8.0Hz,1H),7.19(dd,J=4.0Hz,J=8.0Hz,1H),7.10(dd,J=4.0Hz,J=8.0Hz,2H),6.84-6.79(m,1H),5.61-5.56(m,1H),4.36(s,4H),3.71-3.59(m,2H),3.19-3.15(m,3H),2.93(s,3H),2.48-2.47(m,2H),2.06-2.02(m,2H),1.67(d,J=8.0Hz,3H).
实施例5:2-(5-(1-(3,5-二氟苯基)乙氧基)-1H-吲唑-3-基)-N,N-二甲基-4,6-二
氢吡咯并[3,4-d]咪唑-5(1H)甲酰胺
化合物5的合成路线:
合成方法:
合成化合物5:2-(5-(1-(3,5-二氟苯基)乙氧基)-1H-吲唑-3-基)-N,N-二甲基-4,6-二氢吡咯并[3,4-d]咪唑-5(1H)甲酰胺
将中间体4-7(30.0mg,0.05mmol)溶于10ml的二氯甲烷,向体系中加入三光气(15.3mg,0.05mmol),将体系降温至0℃,滴加三乙胺(10.4mg,0.10mmol),反应0.5h,向体系中加入盐酸二甲胺(5.05mg,0.06mmol),升至室温反应。反应完成后,加水淬灭,用DCM萃取,合并有机相,用饱和食盐水洗涤,浓缩。将浓缩物溶于4ml甲醇中,加入2ml浓盐酸,50℃反应5小时,浓缩,溶于5ml甲醇,加0.5ml氨水,浓缩,制备板纯化,得到最终产物4.8mg,收率20.4%。
1H NMR(400MHz,CD3OD)δ7.69(d,J=2.3Hz,1H),7.46(d,J=9.0Hz,1H),7.17(dd,J=9.0,2.4Hz,1H),7.13-7.08(m,2H),6.84-6.78(m,1H),5.58(q,J=6.4Hz,1H),4.71-4.63(m,4H),2.99(s,6H),1.66(d,J=6.4Hz,3H).
实施例6:2-(二甲基氨基)乙基2-(5-(1-(3,5-二氟苯基)乙氧基)-1H-吲唑-3-
基)-4,6-二氢吡咯并[3,4-d]咪唑-5(1H)-羧酸酯
化合物6的合成路线:
合成方法:
合成化合物6:2-(二甲基氨基)乙基2-(5-(1-(3,5-二氟苯基)乙氧基)-1H-吲唑-3-基)-4,6-二氢吡咯并[3,4-d]咪唑-5(1H)-羧酸酯
将中间体4-7(50.0mg,0.08mmol)溶于THF中,冷却到0℃,加入三光气(25.1mg,0.08mmol),反应5分钟,缓慢加入三乙胺(84.2mg,0.80mmol),室温反应0.5小时,向反应液中加2-(二甲基氨基)乙烷-1-醇(38.1mg,0.42mmol)和DMAP(5.0mg,0.04mmol),加热到60反应1.5小时,向反应液中加水,用EA萃取2次,合并有机相,用饱和食盐水洗涤,无水硫酸钠干燥,浓缩,硅胶板纯化,将纯化后的浓缩物溶于2ml甲醇中,加入1ml的浓盐酸,50℃反应6小时,浓缩,溶于3ml的甲醇中,加入0.5ml的氨水,浓缩,硅胶板纯化,得到终产物15mg,收率35.0%。
1H NMR(400MHz,CD3OD)δ7.68(d,J=4.0Hz,1H),7.46(d,J=8.0Hz,1H),7.20-7.14(m,1H),7.14-7.08(m,2H),6.85-6.78(m,1H),5.58(q,J=8.0Hz,1H),4.72-4.50(m,4H),4.35(t,J=8.0Hz,2H),2.82-2.74(m,2H),2.41(s,6H),1.66(d,J=8.0Hz,3H).
实施例7:(2-(5-(1-(3,5-二氟苯基)乙氧基)-1H-吲唑-3-基)-4,6-二氢吡咯并
[3,4-d]咪唑-5(1H)-基)(1-甲基哌啶-4-基)甲酮
化合物7的合成路线
合成方法:
合成化合物7:(2-(5-(1-(3,5-二氟苯基)乙氧基)-1H-吲唑-3-基)-4,6-二氢吡咯并[3,4-d]咪唑-5(1H)-基)(1-甲基哌啶-4-基)甲酮
在室温条件下,将中间体4-7(30.0mg,0.05mmol),HATU(29.1mg,0.10mmol),N,N-二异丙基乙胺(13.2mg,0.10mmol)和1-甲基哌啶-4-羧酸(14.0mg,0.10mmol)溶于20ml DCM中,搅拌反应2h。加水淬灭反应。用DCM萃取2次,合并有机相,用饱和食盐水洗涤,无水硫酸钠干燥,浓缩。得到的产物溶于2ml甲醇和1ml浓盐酸中,50℃反应2小时,浓缩,溶于3ml甲醇,加1ml氨水,浓缩,制备板纯化,得到最终产物8mg,收43.7%。
1H NMR(400MHz,CD3OD)δ7.67(d,J=1.8Hz,1H),7.45(d,J=9.0Hz,1H),7.21-7.03(m,3H),6.78(t,J=9.1Hz,1H),5.55(q,J=6.2Hz,1H),4.80-4.59(m,4H),3.17-3.14(m,2H),2.75-2.65(m,1H),2.48(s,3H),2.46-2.41(m,2H),1.95-1.90(m,4H),1.63(d,J=6.4Hz,3H).
实施例8:2-(5-(1-(3,5-二氟苯基)乙氧基)-1H-吲唑-3-基)-5-(1-甲基哌啶-4-
基)-4,5,6,7-四氢-3H-咪唑并[4,5-c]吡啶
化合物8的合成路线:
合成方法:
合成中间体8-1:5-(1-(3,5-二氟苯基)-4-基)乙氧基)-1-(四氢-2H-吡喃-2-基)-1H-吲唑-3-腈
将5-(1-(3,5-二氟苯基)乙氧基)-1-(四氢-2H-吡喃-2-基)-1H-吲唑-3-甲醛(200mg,0.52mmol)和三乙胺(157mg,1.55mmol)溶于10ml乙腈中,向溶液中加入盐酸羟胺(53.9mg,0.78mmol),60℃反应3小时。将反应液冷却至室温,向反应液加入三乙胺(419mg,4.14mmol)和乙酸酐(211mg,2.07mmol),80℃反应16小时。向反应液中加水,用二氯甲烷萃取2次,合并有机相,用饱和食盐水洗涤,无水硫酸钠干燥,浓缩,硅胶柱纯化,得中间体8-1145mg,收率73.1%。
1H NMR(400MHz,CDCl3)δ7.64-7.60(m,1H),7.19-7.17(m,1H),6.98-6.97(m,1H),6.93-6.89(m,2H),6.73-6.68(m,1H),5.77-5.73(m,1H),5.34(q,J=6.4Hz,1H),3.94-3.88(m,1H),3.76-3.71(m,1H),2.49-2.41(m,1H),2.14-2.06(m,2H),1.77-1.68(m,3H),1.65(d,J=6.4Hz,3H).
合成中间体8-2:5-(1-(3,5-二氟苯基)乙氧基)-1-(四氢-2H-吡喃-2-基)-1H-吲唑-3-氨基甲酸酯
将中间体8-1(135mg,0.35mmol)溶于10ml甲醇中,向反应液加入甲醇钠(57.1mg,1.06mmol),室温反应16小时,将反应液浓缩除去甲醇,浓缩物中加水,用乙酸乙酯萃取2次,合并有机相,用饱和食盐水洗涤,无水硫酸钠干燥,浓缩得到中间体8-2粗品120mg,收率82.0%。
合成中间体8-3:叔丁基3-(5-(1-(3,5-二氟苯基)乙氧基)-1-(四氢-2H-吡喃-2-基)-1H-吲唑-3-羧酰亚胺基)-4,4-二乙氧基哌啶-1-羧酸酯
将中间体8-2(110mg,0.26mmol)和3-氨基-4,4-二乙氧基哌啶-1-羧酸叔丁酯(91.6mg,0.32mmol)溶于10ml乙醇中,向反应液加入醋酸(31.8mg,0.53mmol),50℃反应16小时,将反应液浓缩除去乙醇,浓缩物用适量甲苯带一下,浓缩得到中间体8-3粗品208mg。
合成中间体8-4:2-(5-(1-(3,5-二氟苯基)乙氧基)-1H-吲唑-3-基)-4,5,6,7-四氢-3H-咪唑[4,5-c]吡啶
将中间体8-3(200mg,0.22mmol)溶于10ml乙醇中,向反应液加入5ml浓盐酸,40℃反应16小时,浓缩,溶于5ml甲醇,加0.5ml氨水,浓缩,硅胶柱纯化,得到中间体8-4 78mg,收率66.2%。
合成化合物8:2-(5-(1-(3,5-二氟苯基)乙氧基)-1H-吲唑-3-基)-5-(1-甲基哌啶-4-基)-4,5,6,7-四氢-3H-咪唑并[4,5-c]吡啶
将中间体8-4(15.0mg,0.04mmol)溶于5ml NMP中,向溶液中加入0.1ml醋酸,55℃搅拌10分钟,冷却至室温,加入1-甲基哌啶-4-酮(4.3mg,0.04mmol),室温反应16小时,加入三乙酰氧基硼氢化钠(16.0mg,0.08mmol)室温反应2小时,加0.5ml氨水调pH,向混合物中加水,用乙酸乙酯萃取2次,合并有机相,用饱和食盐水洗涤,无水硫酸钠干燥,浓缩,制备板纯化,得最终产物4.2mg,收率22.5%。
1H NMR(400MHz,CD3OD)δ7.68(d,J=2.4Hz,1H),7.45(d,J=9.0Hz,1H),7.16(dd,J=9.0,2.4Hz,1H),7.12-7.10(m,2H),6.83-6.79(m,1H),5.58(q,J=6.3Hz,1H),3.80(s,2H),3.17-3.10(m,2H),3.04-3.01(m,2H),2.84-2.80(m,2H),2.73-2.70(m,1H),2.43(s,3H),2.36-2.19(m,2H),2.10-2.03(m,2H),1.84-1.75(m,2H),1.65(d,J=6.3Hz,3H).
实施例9:(S)-5-(1-(3,5-二氟苯基)乙氧基)-3-(5-(((1-甲基哌啶-4-基)甲基)-
1,4,5,6-四氢吡咯并[3,4-d]咪唑-2-基)-1H-吲唑
化合物9的合成路线:
合成方法:
合成中间体9-1:5-((叔丁基二甲基甲硅烷基)氧基)-1-(四氢-2H-吡喃-2-基)-1H-吲唑-3-甲醛
将5-羟基-1-(四氢-2H-吡喃-2-基)-1H-吲唑-3-甲醛(427mg,1.73mmol)和咪唑(177mg,2.60mmol)溶于20ml二氯甲烷中,0℃滴加TBSCl(0.33ml,1.91mmol),加完转移至室温搅拌1小时,反应完毕。向反应液中加水,用二氯甲烷萃取2次,合并有机相,用饱和食盐水洗涤,无水硫酸钠干燥,浓缩得粗品中间体9-1 540mg,收率86.4%。
合成中间体9-2:2-(5-((叔丁基二甲基甲硅烷基)氧基)-1-(四氢-2H-吡喃-2-基)-1H-吲唑-3-基)-3a,4,6,6a-四氢吡咯并[3,4-d]咪唑-5(1H)-羧酸叔丁酯
将中间体9-1(540mg,1.49mmol)溶于20ml叔丁醇中,加入3,4-二氨基吡咯烷-1-羧酸叔丁酯(362mg,1.79mmol),碘(570mg,2.25mmol),碳酸钾(621mg,4.49mmol),升温70℃反应3小时。反应完成后,降至室温,加5%的硫代硫酸钠水溶液淬灭反应,加EA萃取,有机相用饱和食盐水洗涤,无水硫酸钠干燥,浓缩,硅胶柱纯化,得中间体9-2 530mg,收率65.3%。
合成中间体9-3:2-(5-((叔丁基二甲基甲硅烷基)氧基)-1-(四氢-2H-吡喃-2-基)-1H-吲唑-3-基)-4,6-二氢吡咯并[3,4-d]咪唑-5(1H)-羧酸叔丁酯
将中间体9-2(530mg,0.99mmol)溶于10ml DMSO中,加入IBX(548mg,1.96mmol),升温50℃反应3小时。反应完成后,降至室温,加水淬灭反应,加EA萃取,有机相用饱和食盐水洗涤,无水硫酸钠干燥,浓缩,硅胶柱纯化,得中间体9-3 362mg,收率68.4%。
合成中间体9-4:2-(5-((叔丁基二甲基甲硅烷基)氧基)-1-(四氢-2H-吡喃-2-基)-1H-吲唑-3-基)-1-((2-(三甲基甲硅烷基)乙氧基)甲基)-4,6-二氢吡咯并[3,4-d]咪唑-5(1H)-羧酸叔丁酯
将中间体9-3(362mg,0.67mmol)溶于10ml THF中,降温至0℃,加入NaH(60%w/w,32.1mg,1.33mmol),搅拌15min,加入SEMCl(0.14ml,0.80mmol)。加入完毕后升至室温搅拌,反应完成后,加水淬灭,加EA萃取,有机相用饱和食盐水洗涤,无水硫酸钠干燥,浓缩,硅胶柱纯化,得中间体9-4 365mg,收率81.5%。
合成中间体9-5:5-((叔丁基二甲基甲硅烷基)氧基)-1-(四氢-2H-吡喃-2-基)-3-(1-((2-(三甲基甲硅烷基)乙氧基)甲基)-1,4,5,6-四氢吡咯并[3,4-d]咪唑-2-基)-1H-吲唑
将中间体9-4(180mg,0.27mmol)溶于10ml DCM中,加入ZnBr2(303mg,1.34mmol),室温下搅拌。反应完成后,加水淬灭,加DCM萃取,有机相用饱和食盐水洗涤,无水硫酸钠干燥,浓缩,得中间体9-5 153mg,收率99.9%。
合成中间体9-6:4-((2-(5-((叔丁基二甲基甲硅烷基)氧基)-1-(四氢-2H-吡喃-2-基)-1H-吲唑-3-基)-1-((2-(三甲基甲硅烷基)乙氧基)甲基)-4,6-二氢吡咯并[3,4-d]咪唑-5(1H)-基)甲基)哌啶-1-甲酸叔丁酯
将中间体9-5(153mg,0.27mmol)和4-甲酰基哌啶-1-羧酸叔丁酯(68.7mg,0.32mmol)溶于10ml二氯甲烷中,室温搅拌1小时,加入氰基硼氢化钠(25.3mg,0.40mmol),搅拌1小时,反应完成后,加水淬灭,加二氯甲烷萃取,有机相用饱和食盐水洗涤,无水硫酸钠干燥,浓缩,硅胶柱纯化,得中间体9-6 165mg,收率80.1%。
合成中间体9-7:5-((叔丁基二甲基甲硅烷基)氧基)-3-(5-(哌啶-4-基甲基)-1-((2-(三甲基甲硅烷基)乙氧基)甲基)-1,4,5,6-四氢吡咯[3,4-d]咪唑-2-基)-1-(四氢-2H-吡喃-2-基)-1H-吲唑
将中间体9-6(165mg,0.22mmol)溶于10ml DCM中,加入ZnBr2(248mg,1.10mmol),室温下搅拌。反应完成后,加水淬灭,加DCM萃取,有机相用饱和食盐水洗涤,无水硫酸钠干燥,浓缩,得中间体9-7 130mg,收率90.6%。
合成化合物9-8:5-((叔丁基二甲基甲硅烷基)氧基)-3-(5-(((1-甲基哌啶-4-基)甲基)-1-((2-(三甲基甲硅烷基)乙氧基)甲基)-1,4,5,6-四氢吡咯并[3,4-d]咪唑-2-基)-1-(四氢-2H-吡喃-2-基)-1H-吲唑
将中间体9-7(130mg,0.19mmol)和30%甲醛水溶液(17.5mg,0.58mmol)溶于5mlDCM中,搅拌1小时,向溶液中加入三乙酰基硼氢化钠(80.5mg,0.38mmol)。反应完成后,加水淬灭,用DCM萃取,合并有机相,用饱和食盐水洗涤,浓缩,硅胶柱纯化,得中间体9-875.5mg,收率56.9%。
合成化合物9-9:3-(5-((1-甲基哌啶-4-基)甲基)-1-((2-(三甲基甲硅烷基)乙氧基)甲基)-1,4,5,6-四氢吡咯并[3,4-d]咪唑-2-基)-1-(四氢-2H-吡喃-2-基)-1H-吲唑-5-醇
将中间体9-8(40.0mg,0.06mmol)溶于5ml四氢呋喃中,降温至0℃向溶液中加入TBAF的四氢呋喃溶液(1M)(0.12ml,0.12mmol),搅拌30分钟反应完毕,加水淬灭,用乙酸乙酯萃取,合并有机相,用饱和食盐水洗涤,浓缩,得粗品中间体9-9 30.1mg,收率90.1%。
合成中间体9-10:5-((S)-1-(3,5-二氟苯基)乙氧基)-3-(5-(((1-甲基哌啶-4-基)甲基)-1-((2-(三甲基甲硅烷基)乙氧基)甲基)-1,4,5,6-四氢吡咯并[3,4-d]咪唑-2-基)-1-(四氢-2H-吡喃-2-基)-1H-吲唑
将中间体9-9(30.1mg,0.05mmol)和(R)-1-(3,5-二氟苯基)甲磺酸乙酯(12.5mg,0.05mmol)溶于10ml DMF中,加入碳酸铯(35.8mg,0.11mmol),60℃反应2小时,反应完毕。向反应液中加水,用乙酸乙酯萃取2次,合并有机相,用饱和食盐水洗涤,无水硫酸钠干燥,浓缩,硅胶柱纯化,得中间体9-10 19.2mg,收率51.3%。
合成化合物9:(S)-5-(1-(3,5-二氟苯基)乙氧基)-3-(5-(((1-甲基哌啶-4-基)甲基)-1,4,5,6-四氢吡咯并[3,4-d]咪唑-2-基)-1H-吲唑
将中间体9-10(19.2mg,0.02mmol)溶于4ml甲醇中,加入2ml浓盐酸,50℃反应5小时,浓缩,溶于5ml甲醇,加0.5ml氨水,浓缩,制备板纯化,得到最终产物6.2mg,收率46.3%。
1H NMR(400MHz,CD3OD)δ7.64(s,1H),7.46(d,J=9.0Hz,1H),7.15(dd,J=9.1,2.4Hz,1H),7.10-7.05(m,2H),6.81-6.76(m,1H),5.55(q,J=6.4Hz,1H),4.38(s,4H),3.56(d,J=12.4Hz,2H),3.27-3.20(m,2H),3.16-3.06(m,2H),2.89(s,3H),2.21-2.18(m,3H),1.76-1.62(m,5H).
实施例10:1-甲基哌啶-4-基-2-(5-(1-(3,5-二氟苯基)乙氧基)-1H-吲唑-3-基)-
4,6-二氢吡咯并[3,4-d]咪唑-5(1H)-羧酸酯
化合物10的合成路线:
合成方法:
合成化合物10:1-甲基哌啶-4-基-2-(5-(1-(3,5-二氟苯基)乙氧基)-1H-吲唑-3-基)-4,6-二氢吡咯并[3,4-d]咪唑-5(1H)-羧酸酯
将1-甲基哌啶-4-醇(11.0mg,0.10mmol)溶于10ml DCM中,冷却到0℃,加入三光气(15.0mg,0.05mmol),反应5分钟,向溶液中滴加三乙胺(41.2mg,0.40mmol),搅拌0.5h。向反应液中加入中间体4-7(30.0mg,0.05mmol),反应16h。加水淬灭反应。用DCM萃取2次,合并有机相,用饱和食盐水洗涤,无水硫酸钠干燥,浓缩。得到的产物溶于2ml甲醇和1ml浓盐酸中,50℃反应2小时,浓缩,溶于3ml甲醇,加1ml氨水,浓缩,制备板纯化,得到最终产物2.2mg,收17%。
1H NMR(400MHz,CD3OD)δ7.69(d,J=2.2Hz,1H),7.47(d,J=9.1Hz,1H),7.18-7.09(m,3H),6.83-6.79(m,1H),5.58(q,J=6.2Hz,1H),4.87-4.83(m,1H),4.63-4.58(m,4H),2.87-2.79(m,2H),2.62-2.52(m,2H),2.43(s,3H),2.08-2.02(m,2H),1.93-1.84(m,2H),1.66(d,J=6.4Hz,3H)。
实施例11:N-(1-(3,5-二氟苯基)乙基)-3-(5-(哌啶-4-基甲基)-1,4,5,6-四氢吡
咯并[3,4-d]咪唑-2-基)-1H-吲唑-5-胺
化合物11的合成路线:
合成方法:
合成中间体11-1:5-硝基-1-(四氢-2H-吡喃-2-基)-3-(1-((2-(三甲基甲硅烷基)乙氧基)甲基)-1,4,5,6-四氢吡咯并[3,4-d]咪唑-2-基)-1H-吲唑
将中间体1-5(1.40g,2.39mmol)溶于10ml DCM中,加入溴化锌(1.08g,4.79mmol),氮气置换,室温下反应4小时。反应完成后,加水淬灭,加DCM萃取,有机相用饱和食盐水洗涤,无水硫酸钠干燥,浓缩,硅胶柱纯化,得中间体11-1 780mg,收率67.21%。LC-MS m/z(ESI)[M+H]+针对C23H33N6O4Si的计算值为:484.2;测量值为:484.2。
合成中间体11-2:4-((2-(5-硝基-1-(四氢-2H-吡喃-2-基)-1H-吲唑-3-基)-1-((2-(三甲基甲硅烷基)乙氧基)甲基)-4,6-二氢吡咯并[3,4-d]咪唑-5(1H)-基)甲基)哌啶-1-羧酸叔丁酯
将中间体11-1(780mg,1.61mmol)溶于10ml 1,2-二氯乙烷中,加入4-甲酰基哌啶-1-羧酸叔丁酯(686mg,3.22mmol),室温搅拌2h后,加入三乙酰基硼氢化钠(683mg,3.22mmol),室温搅拌1h后,加水淬灭,加DCM萃取,有机相用饱和食盐水洗涤,无水硫酸钠干燥,浓缩,硅胶柱纯化,得中间体11-2 650mg,收率59.01%。LC-MS m/z(ESI)[M+H]+针对C34H52N7O6Si的计算值为:682.4;测量值为:682.4。
合成中间体11-3:4-((2-(5-氨基-1-(四氢-2H-吡喃-2-基)-1H-吲唑-3-基)-1-((2-(三甲基甲硅烷基)乙氧基)甲基)-4,6-二氢吡咯并[3,4-d]咪唑-5(1H)-基)甲基)哌啶-1-羧酸叔丁酯
将中间体11-2(200mg,0.29mmol)溶于5ml乙酸乙酯,加入钯碳(10%w/w,100mg),氢气置换气体,在氢气提供气体环境下室温反应18h,18h后抽滤,浓缩,硅胶柱纯化,得中间体11-3 110mg,收率57.49%。LC-MS m/z(ESI)[M+H]+针对C34H54N7O4Si的计算值为:652.4;测量值为:652.4。
合成中间体11-4:4-((2-(5-((1-(3,5-二氟苯基)乙基)氨基)-1-(四氢-2H-吡喃-2-基)-1H-吲唑-3-基)-1-((2-(三甲基甲硅烷基)乙氧基)甲基)-4,6-二氢吡咯并[3,4-d]咪唑-5(1H)-基)甲基)哌啶-1-羧酸叔丁酯
将中间体11-3(110mg,0.17mmol)溶于5ml甲苯,加入1-(3,5-二氟苯基)乙-1-酮(52.6mg,0.34mmol),90℃反应18h,降温至40℃,加入氰基硼氢化钠(31.8mg,0.51mmol),反应4h,加水淬灭,EA萃取,水洗有机相,干燥,浓缩,硅胶柱纯化,的中间体11-4 36mg,收率27.0%。LC-MS m/z(ESI)[M+H]+针对C42H60F2N7O4Si的计算值为:792.4;测量值为:792.4。
合成化合物11:N-(1-(3,5-二氟苯基)乙基)-3-(5-(哌啶-4-基甲基)-1,4,5,6-四氢吡咯并[3,4-d]咪唑-2-基)-1H-吲唑-5-胺
将中间体11-4(36mg,0.05mmol)溶于4ml甲醇,再加入2ml浓盐酸,50℃反应3h,浓缩,溶于5ml甲醇,加0.5ml氨水,浓缩,制备板纯化,得到最终产物7mg,收率32.2%。LC-MSm/z(ESI)[M+H]+针对C26H30F2N7的计算值为:478.3;测量值为:478.3.
实施例12:
实施例12化合物根据实施例11的合成路线,使用合适的起始原料进行制备,具体如下。
实施例13和实施例14:
实施例13、14的化合物根据实施例3的合成路线,使用合适的起始原料进行制备,具体如下。
实施例15至实施例28:
实施例15至实施例28的化合物根据实施例4的合成路线,使用合适的起始原料进行制备,具体如下。
实施例29:
实施例29化合物根据实施例5的合成路线,使用合适的起始原料进行制备,具体如下。
实施例30和实施例31:
实施例30、31的化合物根据实施例6的合成路线,使用合适的起始原料进行制备,具体如下。
实施例32:
实施例32化合物根据实施例9的合成路线,使用合适的起始原料进行制备,具体如下。
实施例33:
实施例33化合物根据实施例10的合成路线,使用合适的起始原料进行制备,具体如下。
实施例34至实施例46:
实施例34至实施例46的化合物根据实施例4的合成路线,使用合适的起始原料进行制备,具体如下。
实施例47至实施例48:
实施例47至实施例48的化合物根据实施例9的合成路线,使用合适的起始原料进行制备,具体如下。
活性测试实验:对TRKA/B/C激酶抑制活性的测定
1.材料和设备
2.实验步骤
2.1制备1x激酶反应缓冲液:
1倍体积的5X激酶反应缓冲液和4倍体积的水;5mM MgCl2;1mM DTT。
2.2激酶和底物准备:
2.5X底物混合物配制
2.3化合物筛选:
1)在稀释板中用DMSO对化合物进行4倍梯度稀释,化合物起始浓度为1000nM。
2)将化合物50倍稀释到1X激酶反应缓冲液中,在振荡器上震荡20分钟。
3)用1X的酶反应缓冲液配制准备2X激酶。
4)向反应板中每孔加入2μl激酶(步骤3中配制)。
5)向每孔加入1μl在缓冲液中稀释好的化合物,用封板膜封住板子1000g离心30秒,室温放置10分钟。
6)用1X的酶反应缓冲液配制4x ATP&sub混合液,向反应板中加入1μl 4x ATP&sub混合液。
7)用封板膜封住板子1000g离心30秒,室温反应60分钟。
8)转移4μl ADP-Glo到384反应板中1000rpm/min,离心1min,25℃孵育40min。
9)转移8μl Detection溶液到384反应板中1000rpm/min,离心1min,25℃孵育40min。
10)使用Biotek多功能读板机读取RLU(Relative luminescence unit)信号。信号强度用于表征激酶的活性程度。
3.数据分析
3.1抑制率计算如下:
化合物抑制率(%inh)=100%-(化合物-阳性对照)/(阴性对照-阳性对照)*100%
3.2计算IC50并绘制化合物的抑制曲线:
利用以下非线性拟合公式来得到化合物的IC50(半数抑制浓度):用Graphpad 6.0软件进行数据分析。
Y=Bottom+(Top-Bottom)/(1+10^((LogIC50-X)*Hill Slope))
X:化合物浓度log值Y:抑制率(%inhibition)
3.3结果验证
数据从Biotek中导出,人工分析。比值转化为抑制率,IC50通过抑制率由PrismGraphPad 6.0计算。IC50通过比值再次计算,以验证结果准确性。
3.4质量控制
Z factor>0.5;S/B>2
阳性对照IC50在历次平均值3倍以内
4.结果
测试结果见下面的表1。
表1:各实施例化合物对TRKA/B/C激酶的抑制作用
测试的各实施例化合物对于TRKA、TRKB、TRKC激酶均显示出与LOXO-101相似或更好的抑制活性。
虽然已经阐明并描述了本发明的特定实施方式,但并不意味着这些实施方式阐明了并描述了本发明的所有可能形式。更确切地,用在本说明书中的文字仅仅是描述性的文字并非限制性的。对于本领域技术人员明显的是,在不脱离本公开的一般范围的情况下,可以进行各种其他改变和修改。因此,在所附权利要求中,旨在包括在本发明范围内的所有这些改变和修改。
Claims (16)
1.一种式(I)的化合物:
或其同位素标记化合物、或其光学异构体、几何异构体、互变异构体、或其药学上可接受的盐,其中:
R1、R2各自独立地选自CN和卤素;
R3选自H和C1-4烷基;
R6为H;
X为连接键、O、S或(NR4),其中R4选自:H、C1-4烷基;
n=1或2;
L为(C=O)、(O=S=O)、CRaRb或连接键,其中Ra和Rb各自独立地选自:H或C1-4烷基;
R5选自H、C1-6烷基、C1-6烷氧基、C3-7脂环基、3-10元杂脂环基、C6-12双环脂环基、6-12元双环杂脂环基、-C1-4烷基-(3-10元杂脂环基)、-N(R10)(R11)和-OR12,
其中所述C1-6烷基、C1-6烷氧基、C3-7脂环基、3-10元杂脂环基、C6-12双环脂环基、6-12元双环杂脂环基、-C1-4烷基-(3-10元杂脂环基)各自任选地被0、1、2、3或4个R5a取代,且R5a独立选自卤素、-OH、-CN、C1-4烷基、C1-4卤代烷基、C1-4烷氧基、C1-4卤代烷氧基、C3-7脂环基、-N(R13)(R14)、-C(=O)-R15和-C(=O)-OR15;
且R10、R11、R12、R13、R14、和R15各自在每次出现时独立地选自:H、C1-6烷基、C1-6卤代烷基、C3-7脂环基、3-10元杂脂环基、C5-8芳基、5-7元杂芳基、C7-11双环芳基、7-11元双环杂芳基、-C1-4烷基-(C3-7脂环基)、-C1-4烷基-(3-10元杂脂环基)、-C1-4烷基-(C6-12双环脂环基)、-C1-4烷基-(6-12元双环杂脂环基)、-C1-4烷基-(C8-15元三环脂环基)、-C1-4烷基-(8-15元三环杂脂环基)、-C1-4烷基-(C5-8芳基)和-C1-4烷基-(5-10元杂芳基),其中该群组内的各个选项任选地被0、1、2、3或4个各自独立选自以下群组的取代基所取代:卤素、-OH、-NH2、-NH(CH3)、-N(CH3)2、-CN、-NO2、-SF5、-SH、-S-C1-4烷基、氧代、C1-4烷基、C2-6烯基、C2-6炔基、C3-7脂环基、3-10元杂脂环基、C5-8芳基、5-7元杂芳基、C7-11双环芳基、7-11元双环杂芳基、C1-4羟烷基、-S-C1-4烷基、-C(=O)H、-C(=O)-C1-4烷基、-C(=O)-O-C1-4烷基、-C(=O)-NH2、-C(=O)-N(C1-4烷基)2、C1-4卤代烷基、C1-4烷氧基和C1-4卤代烷氧基;或者R10、R11以及与它们相连的原子共同形成3-14元环;或者R13、R14以及与它们相连的原子共同形成3-14元环。
2.根据权利要求1所述的化合物或其同位素标记化合物、或其光学异构体、几何异构体、互变异构体、或其药学上可接受的盐,其中X为-O-或-NH-。
3.根据权利要求1-2中任一项所述的化合物或其同位素标记化合物、或其光学异构体、几何异构体、互变异构体、或其药学上可接受的盐,其中R1和R2各自独立地选自:F、Cl和Br。
4.根据权利要求1-2中任一项所述的化合物或其同位素标记化合物、或其光学异构体、几何异构体、互变异构体、或其药学上可接受的盐,其中L为-(C=O)-、-(O=S=O)-、-CH2-、-C(CH3)2-、-CH(CH3)-或连接键。
5.根据权利要求1-2中任一项所述的化合物或其同位素标记化合物、或其光学异构体、几何异构体、互变异构体、或其药学上可接受的盐,其中R5选自H、C1-6烷基、C1-6烷氧基、C3-6脂环基、4-6元杂脂环基、-C1-4烷基-(3-10元杂脂环基)、-N(R10)(R11),其中所述C1-6烷基、C1-6烷氧基、C3-6脂环基、4-6元杂脂环基、-C1-4烷基-(3-10元杂脂环基)、各自任选地被0、1、2、3或4个R5a取代,且R5a独立选自卤素、-OH、-CN、C1-4烷基、C1-4卤代烷基、C1-4烷氧基、C1-4卤代烷氧基、C3-7脂环基;
且R10、R11和R12各自在每次出现时独立地选自:H、C1-6烷基、C1-6卤代烷基、C3-7脂环基、3-10元杂脂环基,其中该群组内的各个选项任选地被0、1、2、3或4个各自独立选自以下群组的取代基所取代:卤素、-OH、-NH2、氧代、C1-4烷基、C1-4羟烷基、C1-4卤代烷基、C1-4烷氧基和C1-4卤代烷氧基;或者R10、R11以及与它们相连的原子共同形成3-8元环。
6.根据权利要求5所述的化合物或其同位素标记化合物、或其光学异构体、几何异构体、互变异构体、或其药学上可接受的盐,其中R5选自H、甲基、乙基、丙基、丁基、戊基、己基、甲氧基、乙氧基、丙氧基、丁氧基、戊氧基、己氧基、环丙基、环丁基、环戊基、环己基、环庚基、哌嗪基、哌啶基、吗啉基、吡咯烷基,其中的甲基、乙基、丙基、丁基、戊基、己基、甲氧基、乙氧基、丙氧基、丁氧基、戊氧基、己氧基、环丙基、环丁基、环戊基、环己基、环庚基、哌嗪基、哌啶基、吗啉基、吡咯烷基各自任选地被1或2个R5a取代,且R5a独立选自卤素、-OH、-CN、C1-4烷基、C1-4卤代烷基和C1-4烷氧基。
7.如下化合物或其同位素标记化合物、或其光学异构体、几何异构体、互变异构体、或其药学上可接受的盐,其中所述化合物选自:
N-(1-(1-(3,5-二氟苯基)乙基)-3-(1,4,5,6-四氢吡咯并[3,4-d]咪唑-2-基)-1H-吲唑-5-胺;
N-(3,5-二氟苄基)-3-(5-(哌啶-4-基甲基)-1,4,5,6-四氢吡咯并[3,4-d]咪唑-2-基)-1H-吲唑-5-胺;
5-(3,5-二氟苄基)-3-(5-(甲基磺酰基)-1,4,5,6-四氢吡咯并[3,4-d]咪唑-2-基)-1H-吲唑;
5-(1-(3,5-二氟苯基)乙氧基)-3-(5-(1-甲基哌啶-4-基)-1,4,5,6-四氢吡咯并[3,4-d]咪唑-2-基)-1H-吲唑;
2-(5-(1-(3,5-二氟苯基)乙氧基)-1H-吲唑-3-基)-N,N-二甲基-4,6-二氢吡咯并[3,4-d]咪唑-5(1H)甲酰胺;
2-(二甲基氨基)乙基2-(5-(1-(3,5-二氟苯基)乙氧基)-1H-吲唑-3-基)-4,6-二氢吡咯并[3,4-d]咪唑-5(1H)-羧酸酯;
(2-(5-(1-(3,5-二氟苯基)乙氧基)-1H-吲唑-3-基)-4,6-二氢吡咯并[3,4-d]咪唑-5(1H)-基)(1-甲基哌啶-4-基)甲酮;
2-(5-(1-(3,5-二氟苯基)乙氧基)-1H-吲唑-3-基)-5-(1-甲基哌啶-4-基)-4,5,6,7-四氢-3H-咪唑并[4,5-c]吡啶;
(S)-5-(1-(3,5-二氟苯基)乙氧基)-3-(5-(((1-甲基哌啶-4-基)甲基)-1,4,5,6-四氢吡咯并[3,4-d]咪唑-2-基)-1H-吲唑;
1-甲基哌啶-4-基-2-(5-(1-(3,5-二氟苯基)乙氧基)-1H-吲唑-3-基)-4,6-二氢吡咯并[3,4-d]咪唑-5(1H)-羧酸酯;
N-(1-(3,5-二氟苯基)乙基)-3-(5-(哌啶-4-基甲基)-1,4,5,6-四氢吡咯并[3,4-d]咪唑-2-基)-1H-吲唑-5-胺;
N-(1-(1-,3,5-二氟苯基)乙基)-3-(5-(((1-甲基哌啶-4-基)甲基)-1,4,5,6-四氢吡咯并[3,4-d]咪唑-2-基)-1H-吲唑-5-胺;
环丙基(2-(5-(3,5-二氟苄基)-1H-吲唑-3-基)-4,6-二氢吡咯并[3,4-d]咪唑-5(1H)-基)甲酮;
5-(3,5-二氟苄基)-3-(5-(1-甲基哌啶-4-基)-1,4,5,6-四氢吡咯并[3,4-d]咪唑-2-基)-1H-吲唑;
5-(1-(3,5-二氟苯基)乙氧基)-3-(5-(((1-甲基哌啶-4-基)甲基)-1,4,5,6-四氢吡咯并[3,4-d]咪唑-2-基)-1H-吲唑;
5-(1-(3,5-二氟苯基)乙氧基)-3-(5-(哌啶-4-基甲基)-1,4,5,6-四氢吡咯并[3,4-d]咪唑-2-基)-1H-吲唑;
5-(1-(3,5-二氟苯基)乙氧基)-3-(5-(((1-乙基哌啶-4-基)甲基)-1,4,5,6-四氢吡咯并[3,4-d]咪唑-2-基)-1H-吲唑;
2-(2-(5-(1-(3,5-二氟苯基)乙氧基)-1H-吲唑-3-基)-4,6-二氢吡咯并[3,4-d]咪唑-5(1H)-基)-N,N-二甲基乙-1-胺;
1-(4-((2-(5-(1-(3,5-二氟苯基)乙氧基)-1H-吲唑-3-基)-4,6-二氢吡咯并[3,4-d]咪唑-5(1H)-基)甲基)哌啶-1-基)乙-1-酮;
5-(1-(3,5-二氟苯基)乙氧基)-3-(5-(((1-甲基吡咯烷-3-基)甲基)-1,4,5,6-四氢吡咯并[3,4-d]咪唑-2-基)-1H-吲唑;
5-(1-(3,5-二氟苯基)乙氧基)-3-(5-(2-(1-甲基哌啶-4-基)乙基)-1,4,5,6-四氢吡咯并[3,4-d]咪唑-2-基)-1H-吲唑;
5-(1-(3,5-二氟苯基)乙氧基)-3-(5-(((1-异丙基哌啶-4-基)甲基)-1,4,5,6-四氢吡咯并[3,4-d]咪唑-2-基)-1H-吲唑;
5-(1-(3,5-二氟苯基)乙氧基)-3-(5-(1-(1-甲基哌啶-4-基)乙基)-1,4,5,6-四氢吡咯并[3,4-d]咪唑-2-基)-1H-吲唑;
5-(1-(3,5-二氟苯基)乙氧基)-3-(5-(哌啶-3-基甲基)-1,4,5,6-四氢吡咯并[3,4-d]咪唑-2-基)-1H-吲唑;
5-(1-(3,5-二氟苯基)乙氧基)-3-(5-(哌啶-2-基甲基)-1,4,5,6-四氢吡咯并[3,4-d]咪唑-2-基)-1H-吲唑;
5-(1-(3,5-二氟苯基)乙氧基)-3-(5-((1-甲基氮杂环丁烷-3-基)甲基)-1,4,5,6-四氢吡咯并[3,4-d]咪唑-2-基)-1H-吲唑;
3-(5-((1-环丁基哌啶-4-基)甲基)-1,4,5,6-四氢吡咯并[3,4-d]咪唑-2-基)-5-(1-(3,5-二氟苯基)乙氧基)-1H-吲唑;
5-(1-(3,5-二氟苯基)乙氧基)-3-(5-(((1-异丙基-4-甲基哌啶-4-基)甲基)-1,4,5,6-四氢吡咯并[3,4-d]咪唑-2-基)-1H-吲唑;
(2-(5-(1-(3,5-二氟苯基)乙氧基)-1H-吲唑-3-基)-4,6-二氢吡咯并[3,4-d]咪唑-5(1H)-基)(4-甲基哌嗪-1-基)甲酮;
1-甲基吡咯烷-3-基-2-(5-(1-(3,5-二氟苯基)乙氧基)-1H-吲唑-3-基)-4,6-二氢吡咯并[3,4-d]咪唑-5(1H)-羧酸酯;
1-甲基氮杂环丁烷-3-基-2-(5-(1-(3,5-二氟苯基)乙氧基)-1H-吲唑-3-基)-4,6-二氢吡咯并[3,4-d]咪唑-5(1H)-羧酸酯;
(R)-5-(1-(3,5-二氟苯基)乙氧基)-3-(5-(((1-甲基哌啶-4-基)甲基)-1,4,5,6-四氢吡咯并[3,4-d]咪唑-2-基)-1H-吲唑;
1-甲基哌啶-3-基-2-(5-(1-(3,5-二氟苯基)乙氧基)-1H-吲唑-3-基)-4,6-二氢吡咯并[3,4-d]咪唑-5(1H)-羧酸酯;
5-(1-(3,5-二氟苯基)乙氧基)-3-(5-(1-(1-甲基氮杂环丁烷-3-基)乙基)-1,4,5,6-四氢吡咯并[3,4-d]咪唑-2-基)-1H-吲唑;
4-(2-(5-(1-(3,5-二氟苯基)乙氧基)-1H-吲唑-3-基)-4,6-二氢吡咯并[3,4-d]咪唑-5(1H)-基)-N,N-二甲基环己烷-1-胺;
4-((2-(5-(1-(3,5-二氟苯基)乙氧基)-1H-吲唑-3-基)-4,6-二氢吡咯并[3,4-d]咪唑-5(1H)-基)甲基)哌啶-1-羧酸甲酯;
5-(1-(3,5-二氟苯基)乙氧基)-3-(5-(1-乙基哌啶-4-基)-1,4,5,6-四氢吡咯并[3,4-d]咪唑-2-基)-1H吲唑;
5-(1-(3,5-二氟苯基)乙氧基)-3-(5-(2-甲基-2-氮杂螺[3.3]庚烷-6-基)-1,4,5,6-四氢吡咯并[3,4-d]咪唑-2-基)-1H-吲唑;
5-(1-(3,5-二氟苯基)乙氧基)-3-(5-(7-甲基-7-氮杂螺[3.5]壬烷-2-基)-1,4,5,6-四氢吡咯并[3,4-d]咪唑-2-基)-1H-吲唑;
5-(1-(3,5-二氟苯基)乙氧基)-3-(5-(1-甲基吡咯烷-3-基)-1,4,5,6-四氢吡咯并[3,4-d]咪唑-2-基)-1H吲唑;
5-(1-(3,5-二氟苯基)乙氧基)-3-(5-(吡咯烷-2-基甲基)-1,4,5,6-四氢吡咯并[3,4-d]咪唑-2-基)-1H-吲唑;
5-(1-(3,5-二氟苯基)乙氧基)-3-(5-(1-乙基哌啶-3-基)-1,4,5,6-四氢吡咯并[3,4-d]咪唑-2-基)-1H吲唑;
3-(2-(5-(1-(3,5-二氟苯基)乙氧基)-1H-吲唑-3-基)-4,6-二氢吡咯并[3,4-d]咪唑-5(1H)-基)-N,N-二甲基环丁烷-1-胺;
3-(2-(5-(1-(3,5-二氟苯基)乙氧基)-1H-吲唑-3-基)-4,6-二氢吡咯并[3,4-d]咪唑-5(1H)-基)-N,N-二甲基环己烷-1-胺;
3-(2-(5-(1-(3,5-二氟苯基)乙氧基)-1H-吲唑-3-基)-4,6-二氢吡咯并[3,4-d]咪唑-5(1H)-基)-N,N-二甲基环戊烷-1-胺;
3-氟-5-(1-(3-(5-((1-甲基哌啶-4-基)甲基)-1,4,5,6-四氢吡咯并[3,4-d]咪唑-2-基)-1H-吲哚-5-基)氧基)乙基)苯甲腈;
5-(1-(3,5-二氟苯基)丙氧基)-3-(5-((1-甲基哌啶-4-基)甲基)-1,4,5,6-四氢吡咯并[3,4-d]咪唑-2-基)-1H-吲唑。
8.如下化合物或其同位素标记化合物、或其光学异构体、几何异构体、互变异构体、或其药学上可接受的盐,其中所述化合物选自:
5-(1-(3,5-二氟苯基)乙氧基)-3-(5-(1-(甲基磺酰基)哌啶-4-基)甲基)-1,4,5,6-四氢吡咯并[3,4-d]咪唑-2-基)-1H吲唑。
9.根据权利要求1所述的化合物或其同位素标记化合物、或其光学异构体、几何异构体、互变异构体、或其药学上可接受的盐,其中所述式(I)化合物为下面式(Ia)所示的化合物:
其中,X为-O-或-(NH)-;L、n、R3、R5、R6如权利要求1所定义。
10.根据权利要求1所述的化合物或其同位素标记化合物、或其光学异构体、几何异构体、互变异构体、或其药学上可接受的盐,其中所述式(I)化合物为下面式(Ib)所示的化合物:
其中,L、n、R5、R6如权利要求1所定义。
11.根据权利要求1所述的化合物或其同位素标记化合物、或其光学异构体、几何异构体、互变异构体、或其药学上可接受的盐,其中所述式(I)化合物为下面式(Ic)所示的化合物:
其中,X为-O-或-(NH)-;n、R3、R5、R6、Ra、Rb如权利要求1所定义。
12.根据权利要求1所述的化合物或其同位素标记化合物、或其光学异构体、几何异构体、互变异构体、或其药学上可接受的盐,其中所述式(I)化合物为下面式(IIa)所示的化合物:
其中,n、R5、R6、Ra、Rb如权利要求1所定义。
13.根据权利要求1所述的化合物或其同位素标记化合物、或其光学异构体、几何异构体、互变异构体、或其药学上可接受的盐,其中所述式(I)化合物为下面式(IIb)所示的化合物:
其中,n、R5、R6、Ra、Rb如权利要求1所定义。
14.一种药物组合物,其包含根据权利要求1-13中任一项所述的化合物或其同位素标记化合物、或其光学异构体、几何异构体、互变异构体、或其药学上可接受的盐,以及一种或多种药学上可接受的载体、佐剂或赋形剂。
15.根据权利要求1-13中任一项所述的化合物或其同位素标记化合物、或其光学异构体、几何异构体、互变异构体、或其药学上可接受的盐或者根据权利要求14所述的药物组合物在制备用于治疗与TRK激酶或NTRK基因相关的疾病或病症的药物中的用途。
16.根据权利要求15所述的用途,其中所述与TRK激酶或NTRK基因相关的疾病和病症选自:癌症、疼痛、炎症、神经变性疾病和细胞增殖疾病,并且所述癌症选自乳腺癌、结肠直肠癌、黑色素瘤、肺癌、胃癌、甲状腺癌、神经胶母细胞瘤和成神经细胞瘤。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2021106852645 | 2021-06-21 | ||
CN202110685264 | 2021-06-21 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN115043844A CN115043844A (zh) | 2022-09-13 |
CN115043844B true CN115043844B (zh) | 2024-05-17 |
Family
ID=83163291
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210705163.4A Active CN115043844B (zh) | 2021-06-21 | 2022-06-21 | Trk激酶抑制剂化合物及其用途 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20240317760A1 (zh) |
EP (1) | EP4357347A1 (zh) |
JP (1) | JP2024524236A (zh) |
CN (1) | CN115043844B (zh) |
WO (1) | WO2022268080A1 (zh) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102056927A (zh) * | 2008-05-13 | 2011-05-11 | Irm责任有限公司 | 作为激酶抑制剂的稠合含氮杂环及其组合物 |
WO2012034091A1 (en) * | 2010-09-09 | 2012-03-15 | Irm Llc | Imidazo [1, 2] pyridazin compounds and compositions as trk inhibitors |
CN103534257A (zh) * | 2011-04-05 | 2014-01-22 | 辉瑞有限公司 | 作为原肌球蛋白相关激酶抑制剂的吡咯并[2,3-d]嘧啶衍生物 |
WO2017077283A1 (en) * | 2015-11-03 | 2017-05-11 | Topivert Pharma Limited | 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors |
CN111606908A (zh) * | 2019-02-25 | 2020-09-01 | 河南迈英诺医药科技有限公司 | Jak抑制剂化合物及其用途 |
CN112979654A (zh) * | 2019-12-16 | 2021-06-18 | 成都倍特药业有限公司 | 杂芳基稠环化合物、其制备方法及应用 |
-
2022
- 2022-06-21 CN CN202210705163.4A patent/CN115043844B/zh active Active
- 2022-06-21 US US18/572,862 patent/US20240317760A1/en active Pending
- 2022-06-21 EP EP22827573.1A patent/EP4357347A1/en active Pending
- 2022-06-21 WO PCT/CN2022/100186 patent/WO2022268080A1/zh active Application Filing
- 2022-06-21 JP JP2023579048A patent/JP2024524236A/ja active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102056927A (zh) * | 2008-05-13 | 2011-05-11 | Irm责任有限公司 | 作为激酶抑制剂的稠合含氮杂环及其组合物 |
WO2012034091A1 (en) * | 2010-09-09 | 2012-03-15 | Irm Llc | Imidazo [1, 2] pyridazin compounds and compositions as trk inhibitors |
CN103534257A (zh) * | 2011-04-05 | 2014-01-22 | 辉瑞有限公司 | 作为原肌球蛋白相关激酶抑制剂的吡咯并[2,3-d]嘧啶衍生物 |
WO2017077283A1 (en) * | 2015-11-03 | 2017-05-11 | Topivert Pharma Limited | 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors |
CN111606908A (zh) * | 2019-02-25 | 2020-09-01 | 河南迈英诺医药科技有限公司 | Jak抑制剂化合物及其用途 |
CN112979654A (zh) * | 2019-12-16 | 2021-06-18 | 成都倍特药业有限公司 | 杂芳基稠环化合物、其制备方法及应用 |
Also Published As
Publication number | Publication date |
---|---|
CN115043844A (zh) | 2022-09-13 |
US20240317760A1 (en) | 2024-09-26 |
EP4357347A1 (en) | 2024-04-24 |
WO2022268080A1 (zh) | 2022-12-29 |
JP2024524236A (ja) | 2024-07-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10233186B2 (en) | Inhibitors of activin receptor-like kinase | |
CN111606908B (zh) | Jak抑制剂化合物及其用途 | |
AU2018312836B2 (en) | Novel heterocyclic compounds as CDK8/19 inhibitors | |
EA025186B1 (ru) | НОВЫЕ 4-(ЗАМЕЩЕННЫЙ АМИНО)-7Н-ПИРРОЛО[2,3-d]ПИРИМИДИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ LRRK2 | |
CN114524818B (zh) | Fgfr抑制剂化合物及其用途 | |
WO2014134772A1 (en) | Compounds inhibiting leucine-rich repeat kinase enzyme activity | |
CN116323625A (zh) | 杂环类衍生物、其制备方法及其医药上的用途 | |
EA029842B1 (ru) | 2,6-замещенные пуриновые производные и их применение в лечении пролиферативных заболеваний | |
CN113874015B (zh) | Ripk2的噻吩并吡啶抑制剂 | |
KR20190092549A (ko) | Cdk4/6 억제제 | |
TW202208379A (zh) | 新穎的巨環lrrk2激酶抑制劑 | |
WO2016192630A1 (zh) | 一类具有激酶抑制活性的化合物、制备方法和用途 | |
CN113316578B (zh) | 杂环化合物、包含其的药物组合物及其制备方法和用途 | |
WO2019062657A1 (zh) | 氮杂环类衍生物、其制备方法及其医药用途 | |
CN110655520A (zh) | 嘧啶并环化合物及其制备方法和应用 | |
WO2024040109A2 (en) | Kras inhibitors | |
CN115043844B (zh) | Trk激酶抑制剂化合物及其用途 | |
WO2022271749A1 (en) | Heterocyclic egfr inhibitors for use in the treatment of cancer | |
CN114591319B (zh) | 四氢吡啶并嘧啶类衍生物及其用途 | |
JP2024502601A (ja) | Tyk2阻害剤 | |
EP3954680A1 (en) | Piperazine amide derivative, preparation method therefor, and use thereof in medicine | |
CN116600808B (zh) | 一类作为kras突变体g12c抑制剂的四氢萘啶类衍生物、其制备方法及其应用 | |
CN117534686A (zh) | TGF-β抑制剂化合物及其用途 | |
CN112521372B (zh) | 一种细胞凋亡蛋白抑制剂及其制备方法和用途 | |
CN116600808A (zh) | 一类作为kras突变体g12c抑制剂的四氢萘啶类衍生物、其制备方法及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |